US20200262860A1 - Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof - Google Patents
Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof Download PDFInfo
- Publication number
- US20200262860A1 US20200262860A1 US16/851,217 US202016851217A US2020262860A1 US 20200262860 A1 US20200262860 A1 US 20200262860A1 US 202016851217 A US202016851217 A US 202016851217A US 2020262860 A1 US2020262860 A1 US 2020262860A1
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- tumor
- amino
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 225
- 239000005450 thionucleoside Substances 0.000 title abstract description 14
- 238000002360 preparation method Methods 0.000 title description 42
- 239000008194 pharmaceutical composition Substances 0.000 title description 20
- 238000000034 method Methods 0.000 claims abstract description 55
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 150000002148 esters Chemical class 0.000 claims abstract description 24
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 230000002159 abnormal effect Effects 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 230000002062 proliferating effect Effects 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 230000037396 body weight Effects 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 18
- 230000000259 anti-tumor effect Effects 0.000 claims description 11
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 241001465754 Metazoa Species 0.000 description 54
- 239000000243 solution Substances 0.000 description 53
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 52
- YXZCYGLOLTWSQI-PQFNHPKFSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O YXZCYGLOLTWSQI-PQFNHPKFSA-N 0.000 description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- -1 nucleotide monophosphate Chemical class 0.000 description 44
- 238000012360 testing method Methods 0.000 description 44
- 239000003814 drug Substances 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- 229910052739 hydrogen Inorganic materials 0.000 description 38
- 239000001257 hydrogen Substances 0.000 description 38
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 37
- 229940079593 drug Drugs 0.000 description 34
- 125000003118 aryl group Chemical group 0.000 description 31
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 27
- 229940005876 gemcitabine injection Drugs 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 229940126062 Compound A Drugs 0.000 description 25
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 125000001424 substituent group Chemical group 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 24
- 229960005277 gemcitabine Drugs 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 24
- 150000002367 halogens Chemical group 0.000 description 24
- 239000002207 metabolite Substances 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 22
- 201000002528 pancreatic cancer Diseases 0.000 description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 description 22
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 206010009944 Colon cancer Diseases 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 20
- 229910052717 sulfur Inorganic materials 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 19
- 238000012512 characterization method Methods 0.000 description 19
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- 125000001072 heteroaryl group Chemical group 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- 125000005842 heteroatom Chemical group 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 208000005718 Stomach Neoplasms Diseases 0.000 description 15
- 206010017758 gastric cancer Diseases 0.000 description 15
- 201000011549 stomach cancer Diseases 0.000 description 15
- 125000003107 substituted aryl group Chemical group 0.000 description 15
- 239000002777 nucleoside Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 150000003833 nucleoside derivatives Chemical class 0.000 description 13
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 11
- 125000002252 acyl group Chemical group 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 0 [1*]OC(=O)C([2*])([6*])N([7*])P(=[Y])(O[3*])OC[C@H]1SC(C)[C@@](C)(F)[C@@H]1O[4*] Chemical compound [1*]OC(=O)C([2*])([6*])N([7*])P(=[Y])(O[3*])OC[C@H]1SC(C)[C@@](C)(F)[C@@H]1O[4*] 0.000 description 10
- 125000002947 alkylene group Chemical group 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- YAQKNCSWDMGPOY-JEDNCBNOSA-N propan-2-yl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)[C@H](C)N YAQKNCSWDMGPOY-JEDNCBNOSA-N 0.000 description 8
- 238000004679 31P NMR spectroscopy Methods 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000005129 aryl carbonyl group Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 125000003368 amide group Chemical group 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 150000007942 carboxylates Chemical group 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 125000004438 haloalkoxy group Chemical group 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical group 0.000 description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 5
- JSPFRZVDIHHDNI-CCPFMDHWSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(1,3-benzodioxol-5-yloxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@@](=O)(OC1=CC2=C(OCO2)C=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O JSPFRZVDIHHDNI-CCPFMDHWSA-N 0.000 description 5
- JSPFRZVDIHHDNI-GOBARBEDSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(1,3-benzodioxol-5-yloxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC2=C(OCO2)C=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O JSPFRZVDIHHDNI-GOBARBEDSA-N 0.000 description 5
- MIILDBHEJQLACD-ZJPIPACBSA-N propan-2-yl (2s)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate Chemical compound O([P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=1C(=C(F)C(F)=C(F)C=1F)F)C1=CC=CC=C1 MIILDBHEJQLACD-ZJPIPACBSA-N 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 4
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 4
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 4
- 101000822020 Homo sapiens Equilibrative nucleoside transporter 1 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- UUYMHZZMARSNRC-BCUQWEDGSA-N ethyl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC)C)O)F)=O UUYMHZZMARSNRC-BCUQWEDGSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- MFWXXEUDIUWCFV-FYPVVNQVSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(4-fluorophenoxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=C(C=C1)F)N[C@H](C(=O)OC(C)C)C)O)F)=O MFWXXEUDIUWCFV-FYPVVNQVSA-N 0.000 description 4
- WBSNYNBMNZFFRZ-STKKXYNCSA-N propan-2-yl 2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]-2-methylpropanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=C1)NC(C(=O)OC(C)C)(C)C)O)F)=O WBSNYNBMNZFFRZ-STKKXYNCSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- LFYLZHGQEVIINJ-SCJDZZBNSA-N (4-fluorophenyl)methyl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC1=CC=C(C=C1)F)C)O)F)=O LFYLZHGQEVIINJ-SCJDZZBNSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- DXMJBRYLHURDLV-QPPQHZFASA-N 4-amino-1-[(2r,4s,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)S1 DXMJBRYLHURDLV-QPPQHZFASA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical class CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000045714 human SLC29A1 Human genes 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940127073 nucleoside analogue Drugs 0.000 description 3
- UFMJKGSNLCYDKU-XUUQOVFCSA-N phenyl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC1=CC=CC=C1)C)O)F)=O UFMJKGSNLCYDKU-XUUQOVFCSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- PDCYOQAYCWIQOV-RCUGMHLUSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(1-benzofuran-6-yloxy)phosphoryl]amino]propanoate Chemical compound C1=2C=COC1=CC(OP(=O)(OC[C@H]1S[C@H]([C@H]([C@@H]1O)F)N1C(=O)N=C(C=C1)N)N[C@H](C(=O)OC(C)C)C)=CC=2 PDCYOQAYCWIQOV-RCUGMHLUSA-N 0.000 description 3
- TZNGCCYTXABPGU-CMDWHRSMSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(2,3-dihydro-1,4-benzodioxin-5-yloxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=2OCCOC=21)N[C@H](C(=O)OC(C)C)C)O)F)=O TZNGCCYTXABPGU-CMDWHRSMSA-N 0.000 description 3
- MFVJLEXCVZFTCR-RCUGMHLUSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(2,3-dihydro-1-benzofuran-6-yloxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC2=C(CCO2)C=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O MFVJLEXCVZFTCR-RCUGMHLUSA-N 0.000 description 3
- OLOVCAFADNRPMO-FYPVVNQVSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(4-bromophenoxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=C(C=C1)Br)N[C@H](C(=O)OC(C)C)C)O)F)=O OLOVCAFADNRPMO-FYPVVNQVSA-N 0.000 description 3
- UWBYDLHWEYKYPW-FYPVVNQVSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(4-chlorophenoxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=C(C=C1)Cl)N[C@H](C(=O)OC(C)C)C)O)F)=O UWBYDLHWEYKYPW-FYPVVNQVSA-N 0.000 description 3
- OXXQMLSGVFYMLM-SHZIDIRHSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-[(7-fluoro-2,3-dihydro-1-benzofuran-4-yl)oxy]phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=C(C2=C1CCO2)F)N[C@H](C(=O)OC(C)C)C)O)F)=O OXXQMLSGVFYMLM-SHZIDIRHSA-N 0.000 description 3
- FNHZLGCVXRDXEO-PSDRXXMJSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-5-fluoro-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1F)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O FNHZLGCVXRDXEO-PSDRXXMJSA-N 0.000 description 3
- XJXQNBWUIMPNEC-RREAMYPJSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)F XJXQNBWUIMPNEC-RREAMYPJSA-N 0.000 description 3
- JVWXHVWBCMBMNA-XTYYNZKISA-N propan-2-yl (2S)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1C([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)(F)F)=O JVWXHVWBCMBMNA-XTYYNZKISA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229910052979 sodium sulfide Inorganic materials 0.000 description 3
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- BLRVRSGSWBOLRH-AYQXTPAHSA-N (2r,3s,4s,5r)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)thiolan-3-ol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1S[C@H](CO)[C@@H](O)[C@@H]1F BLRVRSGSWBOLRH-AYQXTPAHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NIDPJRZOVFIBQB-PXBUCIJWSA-N 4-amino-1-[(2r,3s,4s,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)S1 NIDPJRZOVFIBQB-PXBUCIJWSA-N 0.000 description 2
- YDHFONUSKUASCJ-BYPJNBLXSA-N 4-amino-5-fluoro-1-[(2r,3s,4s,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)S1 YDHFONUSKUASCJ-BYPJNBLXSA-N 0.000 description 2
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108010076278 Adenosine kinase Proteins 0.000 description 2
- 102100032534 Adenosine kinase Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910015844 BCl3 Inorganic materials 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XGDAFNCZURRUCU-RRFQHKSLSA-N C(CC)C(C(=O)NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O)CCC Chemical compound C(CC)C(C(=O)NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O)CCC XGDAFNCZURRUCU-RRFQHKSLSA-N 0.000 description 2
- UONUJIDRVBXKOD-UHFFFAOYSA-N CC(C)(C)C1=C2CCOC2=C(F)C=C1.CC(C)(C)C1=C2OCCOC2=CC=C1.CC(C)(C)C1=CC2=C(C=C1)CCO2.CC(C)(C)C1=CC2=C(C=C1)OCO2.CC(C)(C)C1=CC2=C(C=CO2)C=C1.CC(C)(C)C1=CC=C(Br)C=C1.CC(C)(C)C1=CC=C(Cl)C=C1.CC(C)(C)C1=CC=C(F)C=C1.CC(C)(C)C1=CC=CC=C1 Chemical compound CC(C)(C)C1=C2CCOC2=C(F)C=C1.CC(C)(C)C1=C2OCCOC2=CC=C1.CC(C)(C)C1=CC2=C(C=C1)CCO2.CC(C)(C)C1=CC2=C(C=C1)OCO2.CC(C)(C)C1=CC2=C(C=CO2)C=C1.CC(C)(C)C1=CC=C(Br)C=C1.CC(C)(C)C1=CC=C(Cl)C=C1.CC(C)(C)C1=CC=C(F)C=C1.CC(C)(C)C1=CC=CC=C1 UONUJIDRVBXKOD-UHFFFAOYSA-N 0.000 description 2
- UOJLOGNMOHMEAS-UHFFFAOYSA-N CC(C)(C)C1C=NC2=C1N=C(N)NC2=O.CC1=NC2=C(N=CC2C(C)(C)C)C(N)=N1 Chemical compound CC(C)(C)C1C=NC2=C1N=C(N)NC2=O.CC1=NC2=C(N=CC2C(C)(C)C)C(N)=N1 UOJLOGNMOHMEAS-UHFFFAOYSA-N 0.000 description 2
- MMFJBTMTTRJDJE-UHFFFAOYSA-N CC1=CN(C(C)(C)C)C(=O)N=C1N Chemical compound CC1=CN(C(C)(C)C)C(=O)N=C1N MMFJBTMTTRJDJE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010058222 Deoxyguanosine kinase Proteins 0.000 description 2
- VFXDVCWJZGCPEV-UQVNDFCGSA-N FC1=C(C(=C(C(=C1OP(=O)(OC1=CC=C(C=C1)F)N[C@H](C(=O)OC(C)C)C)F)F)F)F Chemical compound FC1=C(C(=C(C(=C1OP(=O)(OC1=CC=C(C=C1)F)N[C@H](C(=O)OC(C)C)C)F)F)F)F VFXDVCWJZGCPEV-UQVNDFCGSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- IJCKBIINTQEGLY-UHFFFAOYSA-N N(4)-acetylcytosine Chemical compound CC(=O)NC1=CC=NC(=O)N1 IJCKBIINTQEGLY-UHFFFAOYSA-N 0.000 description 2
- CLHFEVVSXOUTJY-LJEDNNMASA-N O1COC2=C1C=CC(=C2)OP(=O)(OC1=C(C(=C(C(=C1F)F)F)F)F)N[C@H](C(=O)OC(C)C)C Chemical compound O1COC2=C1C=CC(=C2)OP(=O)(OC1=C(C(=C(C(=C1F)F)F)F)F)N[C@H](C(=O)OC(C)C)C CLHFEVVSXOUTJY-LJEDNNMASA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 description 2
- KLYGEZMGJJVMPY-XLIXBQIMSA-N benzyl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC1=CC=CC=C1)C)O)F)=O KLYGEZMGJJVMPY-XLIXBQIMSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- BMQDNQMZWUOYGZ-IEOOQLHTSA-N ethyl (2s)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate Chemical compound FC=1C(F)=C(F)C(F)=C(F)C=1OP(=O)(N[C@@H](C)C(=O)OCC)OC1=CC=CC=C1 BMQDNQMZWUOYGZ-IEOOQLHTSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- JHZPMOZLLUNGKJ-UHFFFAOYSA-N propan-2-yl 2-methyl-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate Chemical compound FC1=C(C(=C(C(=C1OP(=O)(OC1=CC=CC=C1)NC(C(=O)OC(C)C)(C)C)F)F)F)F JHZPMOZLLUNGKJ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- KZNKMALAQHEUST-FJXQXJEOSA-N (4-fluorophenyl)methyl (2S)-2-aminopropanoate hydrochloride Chemical compound Cl.C[C@H](N)C(=O)OCc1ccc(F)cc1 KZNKMALAQHEUST-FJXQXJEOSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BNQUEXBUTKQEKQ-AAQVWKPYSA-N *.CC[C@H]1SC(N2C=CC(NC(C)=O)=NC2=O)[C@@H](F)[C@@H]1C.CC[C@H]1SC(OC(C)=O)[C@@H](F)[C@@H]1C.CC[C@H]1SC(OS(C)(=O)=O)[C@@H](F)[C@@H]1C.CC[C@H]1S[C@@H](Br)[C@@H](F)[C@@H]1C.NC1=NC(=O)N([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2F)C=C1 Chemical compound *.CC[C@H]1SC(N2C=CC(NC(C)=O)=NC2=O)[C@@H](F)[C@@H]1C.CC[C@H]1SC(OC(C)=O)[C@@H](F)[C@@H]1C.CC[C@H]1SC(OS(C)(=O)=O)[C@@H](F)[C@@H]1C.CC[C@H]1S[C@@H](Br)[C@@H](F)[C@@H]1C.NC1=NC(=O)N([C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2F)C=C1 BNQUEXBUTKQEKQ-AAQVWKPYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- UVJMVWURCUYFFK-UHFFFAOYSA-N 1-benzofuran-6-ol Chemical compound OC1=CC=C2C=COC2=C1 UVJMVWURCUYFFK-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- IGXSSRPZRAIXQF-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-5-ol Chemical compound O1CCOC2=C1C=CC=C2O IGXSSRPZRAIXQF-UHFFFAOYSA-N 0.000 description 1
- IAFNMXBIRZBSFU-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-6-ol Chemical compound OC1=CC=C2CCOC2=C1 IAFNMXBIRZBSFU-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- PITHYUDHKJKJNQ-UHFFFAOYSA-N 2-propylpentanoyl chloride Chemical compound CCCC(C(Cl)=O)CCC PITHYUDHKJKJNQ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- AGQQMQCDEUJKHK-UHFFFAOYSA-N 7-fluoro-2,3-dihydro-1-benzofuran-4-ol Chemical compound OC1=CC=C(F)C2=C1CCO2 AGQQMQCDEUJKHK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KBYHPUXALOFDBG-WCMTWANKSA-N C#CC#CC#CC#CC#CC#CC.C#CC#CC#CC#CC#CC#CC#C.CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2.CC(C)OC(=O)[C@H](C)C[P@@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2.CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 Chemical compound C#CC#CC#CC#CC#CC#CC.C#CC#CC#CC#CC#CC#CC#C.CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2.CC(C)OC(=O)[C@H](C)C[P@@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2.CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 KBYHPUXALOFDBG-WCMTWANKSA-N 0.000 description 1
- KJAPSUBTABTIIJ-XZMLXKICSA-N C.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(CC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4CCOC4=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4OCCOC4=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)CCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=CO4)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Br)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Cl)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=C(F)C=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C2(F)F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1F.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(Cl)=NC2=C1N=CN2[C@@H]1S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@H]1F.CCCC(CCC)C(=O)CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CCOC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(C)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound C.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(CC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4CCOC4=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4OCCOC4=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)CCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=CO4)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Br)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Cl)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=C(F)C=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C2(F)F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1F.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(Cl)=NC2=C1N=CN2[C@@H]1S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@H]1F.CCCC(CCC)C(=O)CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CCOC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(C)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 KJAPSUBTABTIIJ-XZMLXKICSA-N 0.000 description 1
- ROHYZPFTSHGPDD-DQMNLAEYSA-N C.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(CC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4CCOC4=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4OCCOC4=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)CCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=CO4)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Br)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Cl)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=C(F)C=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1 Chemical compound C.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(CC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4CCOC4=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=C4OCCOC4=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)CCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=CO4)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Br)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(Cl)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=C(F)C=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OC3=CC=CC=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](COP(=O)(C[C@@H](C)C(=O)OCC3=CC=C(F)C=C3)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1.CC1=NC(=O)N([C@@H]2S[C@H](CO[P@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC4=C(C=C3)OCO4)[C@@H](O)[C@@H]2F)C=C1 ROHYZPFTSHGPDD-DQMNLAEYSA-N 0.000 description 1
- KFOYXEFRHDIVDE-KOOKWMBMSA-N C.CC[C@@H]1[C@@H](C)C(F)(F)CS1=O.CC[C@H]1SCC(=O)[C@@H]1C.CC[C@H]1SCC(F)(F)[C@@H]1C.CC[C@H]1SC[C@@H](O)[C@@H]1C.CO[C@@H]1OCC2CSC1[C@H]2C.NC1=NC(=O)N([C@@H]2S[C@H](CO)[C@@H](O)C2(F)F)C=C1.[H][C@]1(CC)O[C@@H](OC)[C@H](OS(C)(=O)=O)[C@H]1C.[H][C@]1(CO)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1C.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1O Chemical compound C.CC[C@@H]1[C@@H](C)C(F)(F)CS1=O.CC[C@H]1SCC(=O)[C@@H]1C.CC[C@H]1SCC(F)(F)[C@@H]1C.CC[C@H]1SC[C@@H](O)[C@@H]1C.CO[C@@H]1OCC2CSC1[C@H]2C.NC1=NC(=O)N([C@@H]2S[C@H](CO)[C@@H](O)C2(F)F)C=C1.[H][C@]1(CC)O[C@@H](OC)[C@H](OS(C)(=O)=O)[C@H]1C.[H][C@]1(CO)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1C.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1O KFOYXEFRHDIVDE-KOOKWMBMSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- NTJYXTROEQLTBS-UHFFFAOYSA-N CC(C)(C)C1=C2CCOC2=C(F)C=C1.CC(C)(C)C1=C2OCCOC2=CC=C1.CC(C)(C)C1=CC2=C(C=C1)CCO2.CC(C)(C)C1=CC2=C(C=C1)OCO2.CC(C)(C)C1=CC2=C(C=CO2)C=C1 Chemical compound CC(C)(C)C1=C2CCOC2=C(F)C=C1.CC(C)(C)C1=C2OCCOC2=CC=C1.CC(C)(C)C1=CC2=C(C=C1)CCO2.CC(C)(C)C1=CC2=C(C=C1)OCO2.CC(C)(C)C1=CC2=C(C=CO2)C=C1 NTJYXTROEQLTBS-UHFFFAOYSA-N 0.000 description 1
- OBTIJGQNWZLHSR-OEQKMRLXSA-N CC(C)OC(=O)C(C)(C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)C(C)(C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 OBTIJGQNWZLHSR-OEQKMRLXSA-N 0.000 description 1
- AGZOWIQDVFUYLN-CUXFJZFRSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=C2CCOC2=C(F)C=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=C2CCOC2=C(F)C=C1 AGZOWIQDVFUYLN-CUXFJZFRSA-N 0.000 description 1
- KFVUZXQLCYFWSW-SFWDVKJTSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=C2OCCOC2=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=C2OCCOC2=CC=C1 KFVUZXQLCYFWSW-SFWDVKJTSA-N 0.000 description 1
- QIYKQZHIIXSGRS-SDIOZUFXSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)CCO2 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)CCO2 QIYKQZHIIXSGRS-SDIOZUFXSA-N 0.000 description 1
- OWKIKXYSRUGTDD-SDIOZUFXSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=CO2)C=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=CO2)C=C1 OWKIKXYSRUGTDD-SDIOZUFXSA-N 0.000 description 1
- OGSACGBHPVQPQI-ZOAAEZCBSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=C(Br)C=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=C(Br)C=C1 OGSACGBHPVQPQI-ZOAAEZCBSA-N 0.000 description 1
- RVVNZQMHEIUOTF-ZOAAEZCBSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=C(Cl)C=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=C(Cl)C=C1 RVVNZQMHEIUOTF-ZOAAEZCBSA-N 0.000 description 1
- TUZWKMXUEZNASJ-RETTUTPMSA-N CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 TUZWKMXUEZNASJ-RETTUTPMSA-N 0.000 description 1
- JIEOSGGTGDZOMQ-IDCKBGKRSA-N CC(C)OC(=O)[C@H](C)C[P@@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 Chemical compound CC(C)OC(=O)[C@H](C)C[P@@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 JIEOSGGTGDZOMQ-IDCKBGKRSA-N 0.000 description 1
- AGCWMMPHASCNSG-GHMIOSEMSA-N CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=C(F)C(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=C(F)C(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 AGCWMMPHASCNSG-GHMIOSEMSA-N 0.000 description 1
- QPVADQAQVOLKMK-BMJACVHSSA-N CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1 QPVADQAQVOLKMK-BMJACVHSSA-N 0.000 description 1
- JIEOSGGTGDZOMQ-ULNQCOTLSA-N CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 Chemical compound CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC2=C(C=C1)OCO2 JIEOSGGTGDZOMQ-ULNQCOTLSA-N 0.000 description 1
- TUZWKMXUEZNASJ-QIHCMUJJSA-N CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 TUZWKMXUEZNASJ-QIHCMUJJSA-N 0.000 description 1
- XJDXCVBWPRYJOT-XVTIFVRZSA-N CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=NC3=C2N=C(Cl)N=C3N)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)C[P@](=O)(OC[C@H]1S[C@@H](N2C=NC3=C2N=C(Cl)N=C3N)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 XJDXCVBWPRYJOT-XVTIFVRZSA-N 0.000 description 1
- YWFWLSIXNORENX-PEDVDRBHSA-N CCCC(CCC)C(=O)CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1 Chemical compound CCCC(CCC)C(=O)CC1=NC(=O)N([C@@H]2S[C@H](CO[P@@](=O)(C[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@H]2F)C=C1 YWFWLSIXNORENX-PEDVDRBHSA-N 0.000 description 1
- SVBRZBUWEPTKST-ZKAJNGKASA-N CCOC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 Chemical compound CCOC(=O)[C@H](C)CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1 SVBRZBUWEPTKST-ZKAJNGKASA-N 0.000 description 1
- NETCJWOJOCCLOM-LHPWJRRSSA-N C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OC1=CC=CC=C1 Chemical compound C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OC1=CC=CC=C1 NETCJWOJOCCLOM-LHPWJRRSSA-N 0.000 description 1
- QOZTWWCMYVOPBW-MEMVBWDCSA-N C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=C(F)C=C1 Chemical compound C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=C(F)C=C1 QOZTWWCMYVOPBW-MEMVBWDCSA-N 0.000 description 1
- CLXMLWJRWITGKT-QMPFDEDJSA-N C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 Chemical compound C[C@H](CP(=O)(OC[C@H]1S[C@@H](N2C=CC(N)=NC2=O)[C@@H](F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 CLXMLWJRWITGKT-QMPFDEDJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- RCMMPUUPLCYPCX-GAPNSNHBSA-N [H][C@]1(C2=[SH]C2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@@H]2CO2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H](C)CC)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H](O)CC)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@@H]1O.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@@H]1OS(=O)(=O)N1C=CN=C1.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F Chemical compound [H][C@]1(C2=[SH]C2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@@H]2CO2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H](C)CC)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H](O)CC)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@@H]1O.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@@H]1OS(=O)(=O)N1C=CN=C1.[H][C@]1([C@H]2COC(C)(C)O2)O[C@@H]2OC(C)(C)O[C@@H]2[C@H]1F RCMMPUUPLCYPCX-GAPNSNHBSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RLMHWGDKMJIEHH-QRPNPIFTSA-N benzyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.C[C@H](N)C(=O)OCC1=CC=CC=C1 RLMHWGDKMJIEHH-QRPNPIFTSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- JCXLZWMDXJFOOI-WCCKRBBISA-N ethyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@H](C)N JCXLZWMDXJFOOI-WCCKRBBISA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- LMINRJFGFHZFDX-FJXQXJEOSA-N phenyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.C[C@H](N)C(=O)OC1=CC=CC=C1 LMINRJFGFHZFDX-FJXQXJEOSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- JSPFRZVDIHHDNI-COEBLGTNSA-N propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-3-hydroxythiolan-2-yl]methoxy-(1,3-benzodioxol-5-yloxy)phosphoryl]amino]propanoate Chemical compound NC1=NC(N(C=C1)[C@H]1[C@H]([C@@H]([C@H](S1)COP(=O)(OC1=CC2=C(OCO2)C=C1)N[C@H](C(=O)OC(C)C)C)O)F)=O JSPFRZVDIHHDNI-COEBLGTNSA-N 0.000 description 1
- FNEIUFZZTHRBKT-UHFFFAOYSA-N propan-2-yl 2-amino-2-methylpropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)C(C)(C)N FNEIUFZZTHRBKT-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- the present invention relates to a novel 4′-thionucleoside compound, to a preparation method thereof, to a pharmaceutical composition comprising the compound, and to use thereof.
- the present invention relates to a phosphamide derivative of a 4′-thionucleoside, to a preparation method thereof, to a pharmaceutical composition comprising the derivative, and to use thereof for the prevention or treatment of an abnormal cell proliferative disease (e.g., tumor, cancer and related disorders) or a viral infectious disease.
- an abnormal cell proliferative disease e.g., tumor, cancer and related disorders
- a natural nucleoside is a glycoside comprising a ribose or a deoxyribose and a base (such as adenine, thymine, guanine, cytosine or uracil), and is an important component of DNA and RNA.
- Artificially synthesized nucleoside analogues are an important class of chemotherapeutic drugs for tumor, and are referred to as antimetabolites. The effect thereof is mainly achieved by affecting enzymatic system in tumor cells, thereby inhibiting the synthesis of DNA and RNA.
- WHO cancer is one of the leading causes of death worldwide.
- drug resistance in cancer cells is ubiquitous, and it is urgently needed to develop new anti-cancer drugs for human health. As such, it is an arduous task in the pharmaceutical industry to develop safe and reliable anti-cancer drugs from various perspectives. Treatment employing an organ specific nucleoside prodrug represents one of the most promising therapeutic methods.
- Nucleoside drugs such as gemcitabine, azacitidine, decitabine, cytarabine, fludarabine, cladribine, 6-azauridine, tiazofurine and atromide, etc., have been widely used for the treatment of various cancers. There are many nucleoside drugs that are currently at different stages of clinical development.
- Gemcitabine is a pyrimidine nucleoside analogue developed by Eli Lilly and Company in the US, and is an important nucleoside-based anticancer drug as a first-line therapeutic agent for advanced pancreatic cancer, advanced non-small cell lung cancer, localized or metastatic bladder cancer and metastatic breast cancer. It has a broad spectrum of anti-tumor activity, and is effective for a variety of additional solid tumors. Gemcitabine generally needs to be administered in combination with paclitaxel, cisplatin, and/or carboplatin.
- Gemcitabine has poor cell permeability, low bioavailability, and a short half-life in cells (between 32 ⁇ 94 min), and thus must be continuously intravenously administered at a high dose (with a recommended dose of 1000 mg/m 2 ), so as to maintain its effective blood drug concentration and toxicity to cancer cells.
- the dose-limiting toxicity induced by the high dose of gemcitabine employed affects clinical efficacy, and results in a series of side effects and safety issues, such as leukopenia, transaminase abnormalities, proteinuria, as well as nausea and vomiting, etc.
- gemcitabine has a number of shortcomings, including lack of tissue specificity which leads to high systemic toxic effects; rapid metabolism and a short plasma half-life; drug resistance in tumors; poor effects achieved through oral administration, common requirement of administration through intravenous injection, a high dosage and severe side effects; poor efficacy achieved when the drug is administered alone, and necessity of co-administration with another anti-cancer drug; etc.
- Gemcitabine has poor oral bioavailability, and thus generally needs to be administrated via intravenous injection.
- the poor oral bioavailability is a result of first-pass metabolism (see Shipley L A., et al., “Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs”. Drug Metabolism & Disposition. 20(6):849-55, 1992).
- gemcitabine when dosed orally, gemcitabine is implicated in causing adverse dose-limiting intestinal lesions characterized by moderate-to-marked loss of mucosal epithelium (atrophic enteropathy) throughout the entire length of the intestinal tract in mice given a single oral (gavage) gemcitabine dose of 167, 333, or 500 mg/kg (see Horton N D et al., “Toxicity of single-dose oral gemcitabine in mice”, American Association for Cancer Research, Poster Presentation, Orlando, Fla., Mar. 27-31, 2004). In a previous study performed on mice, no death or gastrointestinal toxicity was observed when a significant dose was administered intravenously.
- gemcitabine like other nucleoside drugs, is a hydrophilic compound, and thus cannot go through cellular membranes into cells via passive diffusion, but needs a specific transport protein to be delivered into tumor cells. Alteration in the nucleoside transport activity has been considered as an important cause of resistance to gemcitabine.
- Human equilibrative nucleoside transporter 1 (hENT1) is an important transport protein currently identified for the transportation of gemcitabine into tumor cells. As reduction of intracellular drug accumulation would likely result in decreased sensitivity to gemcitabine, scientists at Clavis Pharma, Norway, have synthesized a 5′-elaidic acid ester derivative of gemcitabine, CP-4126, which has significantly improved lipophilicity than that of gemcitabine. Studies show that CP-4126 can get into tumor cells independent of hENT1 transporter, and thus is expected to exhibit a better anti-tumor effect in tumor patients with a low expression of hENT1.
- 4′-thionucleoside refers to a nucleoside analogue with the oxygen atom in the furanose ring replaced by a sulfur atom.
- the synthetic route for 4′-thionucleosides is long and difficult, which greatly limits the study of such compounds.
- U.S. Pat. No. 6,147,058 discloses a 4′-thionucleoside compound which exhibit inhibitory activity in a colon cancer model in nude mice. This compound is shown to have a better effect in inhibiting tumor growth than that of gemcitabine (Cancer Let. 1999, 144, 177-182; Int. J. Cancer, 2005, 114, 1002-1009).
- 5,128,458 discloses a 2′,3′-dideoxy-4′-thioribonucleotides with good effects in the treatment of both a viral infectious disease (such as HIV, hepatitis B or C) and an abnormal cell proliferative disease.
- a viral infectious disease such as HIV, hepatitis B or C
- the 4′-thionucleoside compound has a better effect in inhibiting tumor growth, it also possesses similar shortcomings to those of gemcitabine, such as low oral bioavailability, fast metabolism, multiple adverse effects and drug resistance, etc.
- Resistance to 4′-thionucleoside drugs is a main reason for the short survival period of a patient.
- the major causes for the development of resistance include: 1) lack of corresponding transporter proteins on the surface of tumor cells, which prevents nucleoside drugs from efficiently passing through cellular membranes; 2) low efficiency of the conversion from the drug to the active species as a triphosphate; and 3) metabolism from the drug to an inactive species in the presence of an enzyme.
- a nucleoside drug Upon entry into a body, a nucleoside drug would firstly be phosphorylated to form an active metabolite, monophosphate, through the catalysis of a corresponding kinase, and the monophosphate is then converted to a triphosphate. Monophosphorylation of a nucleoside drug is often a rate-limiting step in the metabolism of the drug.
- TK thymidine kinase
- dCK deoxycytidine kinase
- dGK deoxyguanosine kinase
- AK adenosine kinase
- a 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I) is provided,
- X is hydrogen, C 1-6 alkyl, halogen, N 3 , OH, CN or SH;
- Y is oxygen or sulfur
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R 3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, and optionally substituted C 1-10 acyl
- Q is a pyrimidine base or a purine base having the following structure:
- R 5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl and optionally substituted cycloalkyl;
- Z is hydrogen, optionally substituted C 1-10 alkyl or halogen
- optionally substituted means unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- a pharmaceutical composition or a pharmaceutical formulation comprising the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof, as an active ingredient, and a pharmaceutically acceptable carrier, adjuvant, excipient or equivalent pharmaceutically acceptable medium.
- the pharmaceutical composition or the pharmaceutical formulation can be in a form suitable for administration to a mammal, including a solid preparation, a semi-solid preparation, a liquid preparation, and a gas preparation, etc.
- a use of the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I) in the manufacture of a medicament for the prevention or treatment of an abnormal cell proliferative disease or a viral infectious disease in a mammal is provided.
- the abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof.
- the medicament further comprises an additional anti-tumour agent.
- a method for the prevention or treatment of an abnormal cell proliferative disease and/or a viral infectious disease in a mammal comprises administering to the mammal an effective amount of the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof.
- the abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof in a mammal.
- the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof for the prevention or treatment of an abnormal cell proliferative disease and/or a viral infectious disease in a mammal is provided.
- the abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof in a mammal.
- step 1 is preferably performed in the presence of POCl 3 .
- FIG. 1 shows the effects of the compound of Example 8 (C8) on four different tumor cells at various concentrations.
- An embodiment of the present invention provides a compound of Formula (I),
- X is hydrogen, C 1-6 alkyl, halogen, N 3 , OH, CN or SH;
- Y is oxygen or sulfur
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R 3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, and optionally substituted C 1-10 acyl
- Q is a pyrimidine base or a purine base having the following structure:
- R 5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl and optionally substituted cycloalkyl;
- Z is hydrogen, optionally substituted C 1-10 alkyl or halogen
- optionally substituted means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- Another embodiment of the present invention provides the above compound of Formula (I), wherein:
- Q is a pyrimidine base having the following structure:
- Z is hydrogen, methyl, or halogen
- a further embodiment of the present invention provides the above compound of Formula (I), wherein
- Q is a pyrimidine base having a structure as shown below:
- Z is hydrogen, methyl, or halogen
- a further embodiment of the present invention provides the above compound of Formula (I), wherein:
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- Q is cytosine having the following structural formula:
- a further embodiment of the present invention provides the above compound of Formula (I), wherein Q is selected from
- a further embodiment of the present invention provides the above compound of Formula (I), wherein X is hydrogen or halogen, and the halogen is fluorine, chlorine, bromine or iodine.
- a further embodiment of the present invention provides the above compound of Formula (I), wherein Y is oxygen.
- a further embodiment of the present invention provides the above compound of Formula (I), wherein R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, and optionally substituted aryl (preferably optionally substituted C 6-14 aryl), the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, C 1-6 alkyl, and C 6-14 aryl.
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl, benzyl, and 4-fluorobenzyl.
- a further embodiment of the present invention provides the above compound of Formula (I), wherein R 3 is selected from the group consisting of optionally substituted aryl, preferably optionally substituted C 6-14 aryl, more preferably optionally substituted phenyl, the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, C 1-6 alkyl, and C 1-6 alkoxy, and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 (e.g. 1, 2, or 3) O.
- R 3 has a structure as shown below:
- a further embodiment of the present invention provides the above compound of Formula (I), wherein R 4 is hydrogen.
- a further embodiment of the present invention provides the above compound of Formula (I), wherein R 5 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted C 1-10 alkyl (e.g. hept-4-yl).
- a further embodiment of the present invention provides the above compound of Formula (I), wherein Z is hydrogen, methyl, fluorine or chlorine.
- the present invention encompasses the above compound of Formula (I) obtained by any combination of groups in the definitions of the above-described various embodiments, and would not be constrained by each individual embodiment.
- a further embodiment of the present invention provides the above compound of Formula (I), wherein Q is
- X is hydrogen, C 1-6 alkyl, halogen, N 3 , OH, CN or SH;
- Y is oxygen or sulfur
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R 3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, and optionally substituted C 1-10 acyl
- R 5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl and optionally substituted cycloalkyl;
- Z is hydrogen, methyl or halogen
- optionally substituted means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be independent from each other, or be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- a further embodiment of the present invention provides the above compound of Formula (I), wherein Q is cytosine having the following structural formula:
- X is hydrogen, C 1-6 alkyl, halogen, N 3 , OH, CN or SH;
- Y is oxygen or sulfur
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R 3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, and optionally substituted C 1-10 acyl
- R 5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl and optionally substituted cycloalkyl;
- Z is hydrogen, optionally substituted C 1-10 alkyl or halogen
- optionally substituted means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- a further embodiment of the present invention provides the above compound of Formula (I),
- X is hydrogen, C 1-6 alkyl, halogen, N 3 , OH, CN or SH;
- Y is oxygen or sulfur
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R 2 and R 6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R 3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R 4 is selected from the group consisting of hydrogen, and optionally substituted C 1-10 acyl
- Q is a purine base having the following structure:
- R 5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl and optionally substituted cycloalkyl;
- Z is hydrogen, methyl or halogen
- optionally substituted means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkynyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be independent from each other, or be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- a further embodiment of the present invention provides the above compound of Formula (I), which is a 4′-thio-2,2-difluoronucleoside phosphamide compound (i.e., X in Formula (I) is F), and Q is a pyrimidine group in its definition, and the remaining substituents are each as defined as above.
- X in Formula (I) is F
- Q is a pyrimidine group in its definition, and the remaining substituents are each as defined as above.
- a further embodiment of the present invention provides the above compound of Formula (I), which is a 4′-thio-2,2-difluoronucleoside phosphamide compound (i.e., X in Formula (I) is F), and Q is a cytosine group in its definition, and the remaining substituents are each as defined as above.
- X in Formula (I) is F
- Q is a cytosine group in its definition, and the remaining substituents are each as defined as above.
- the preferred compounds of the present invention are as follows:
- the compound of the present invention has superior pharmaceutical efficacy, including an anti-tumor/anti-cancer effect and an effect on a viral infectious disease, as well as increased liposolubility, improved bioavailability, reduced irritation, and improved absorption. Issues in metabolic rate present in existing drugs are addressed, toxicity is significantly reduced, and safety profile is improved. The pharmacological effect can be achieved through various administration routes.
- the compound of Formula (I) described in the present invention refers to all the compounds covered by Formula (I), pharmaceutically acceptable salts, esters, hydrates, solvates, isomers thereof, or any crystalline form or racemate thereof, or metabolites thereof, or mixtures thereof.
- a further embodiment of the present invention provides a pharmaceutical composition, comprising the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof, as an active ingredient, and a pharmaceutically acceptable carrier, adjuvant, excipient or equivalent pharmaceutically acceptable medium.
- the pharmaceutical composition may comprise the compound of Formula (I) in a unit dose ranging from 0.1-1000 mg, preferably 1-800 mg, more preferably 10-600 mg, particularly preferably 50-450 mg, and most preferably 100-300 mg.
- the pharmaceutical composition may be in a form of e.g., a solid, semi-solid, liquid, or gas preparation.
- the solid preparation is e.g. a tablet, capsule, powder, granule, or suppository, etc.
- the liquid preparation is e.g. a solution, suspension or injection.
- the composition can also be a preparation such as liposome, and microsphere.
- the pharmaceutical composition is in a dosage form suitable for oral administration.
- the pharmaceutical composition can be in a form of a single dose unit or multiple dose units, each of the dose unit comprises a suitable amount of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- a further embodiment of the present invention provides a use of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of an abnormal cell proliferative disease or a viral infectious disease in a mammal.
- the medicament may comprise the compound of Formula (I) in a unit dose ranging from 0.1-1000 mg, preferably 1-800 mg, more preferably 10-600 mg, particularly preferably 50-450 mg, and most preferably 100-300 mg.
- a further embodiment of the present invention provides a method for the treatment or prevention of an abnormal cell proliferative disease or a viral infectious disease in a mammal, wherein the method comprises administering to the mammal an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof.
- a further embodiment of the present invention provides the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof for the treatment or prevention of an abnormal cell proliferative disease or a viral infectious disease in a mammal.
- the abnormal cell proliferative disease or the viral infectious disease is e.g. cancer and/or tumor and related disorders thereof.
- the cancer and/or tumor include(s) tumors and/or cancers and related disorders in esophagus, stomach, intestine, rectum, mouth, pharynx, larynx, lung, colon, breast, uterus, endometrium, ovary, prostate, testis, bladder, kidney, liver, pancreas, bone, connective tissue, skin, eye, brain and central nervous system, as well as thyroid cancer, leukemia, Hodgkin disease, lymphoma and myeloma.
- the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof can be administered in combination with an additional anti-tumour agent for the prevention or treatment of an abnormal cell proliferative disease (such as cancer and/or tumor and related disorders thereof) in a mammal.
- the additional anti-tumor agent refers to a substance with activity against tumor/cancer and related disorders thereof, and includes but is not limited to erlotinib or cisplatin.
- the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof can be administered in combination with an additional anti-viral agent for the prevention or treatment of a viral infectious disease.
- the additional anti-viral agent includes but is not limited to lamivudine, entecavir, nevirapine or stavudine.
- administered in combination encompasses two or more drugs are administered simultaneously, sequentially, or alternatively, and particularly encompasses two or more drugs are prepared into one or more dose units, so as to obtain a pharmaceutical product suitable for administration in combination, which is administered to a mammal in need thereof.
- a further embodiment of the present invention provides a method for preparing the compound of Formula (I), comprising the following steps:
- step 1 is preferably performed in the presence of POCl 3 .
- compound of the present invention generally refers to the scope of compounds defined by above Formula (I), or pharmaceutically acceptable salts, esters, hydrates, solvates, isomers thereof, any crystalline form or racemate thereof, metabolites thereof, or mixtures thereof.
- the term “metabolite” refers to a compound generated in vivo after a drug is applied to a subject in need thereof.
- the term “pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the parent compound, and can be prepared in the following manner: a proton-accepting moiety is partially protonated and/or a proton-donating moiety is partially deprotonated. It should be noted that the partial protonation of the proton-accepting moiety results in a cationic species, the charge of which is balanced by the presence of a physiological anion, while the partial deprotonation of the proton-donating moiety results in an anionic species, the charge of which is balanced by the presence of a physiological cation.
- a pharmaceutically acceptable salt of the compound of Formula (I) includes an acid addition salt and a base addition salt thereof.
- a suitable acid addition salt is formed from an acid which forms a non-toxic salt and includes an inorganic acid and an organic acid.
- a suitable inorganic acid is an acid as defined in the field of chemistry, such as hydrochloric acid, sulfuric acid or phosphoric acid, etc.
- a suitable organic acid includes an organic sulfonic acid, an organic carboxylic acid, or an amino acid, etc.
- a suitable organic sulfonic acid is e.g. C 6-16 aryl sulfonic acid, C 6-16 heteroaryl sulfonic acid, or C 1-16 alkyl sulfonic acid, and a suitable organic carboxylic acid is e.g.
- the organic carboxylic acid can also be e.g. an amino acid, various kinds of which are suitable, particularly natural amino acids which are found as components of proteins.
- salts formed from the above acids include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, t
- a suitable base addition salt is formed from a base which forms non-toxic salts and includes an inorganic base and an organic base.
- a base which forms non-toxic salts and includes an inorganic base and an organic base.
- Specific examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
- the term “isomer” refers to a different compound with a same molecular formula, and includes a stereoisomer.
- stereoisomer is an isomer that merely differs in the arrangement of atoms in space. ⁇ - and ⁇ -indicate the specific stereochemical configuration of a substituent at an asymmetric carbon atom in a chemical structure as drawn.
- the compound of the present invention may have one or more chiral centers, and may, therefore, exist in a variety of stereoisomeric configurations. Due to the presence of these chiral centers, the compound of the present invention can exist as a racemate, a mixture of enantiomers, as well as mixtures of each enantiomer and a diastereomer and of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of “the compound of the present invention”.
- the terms “R” and “S” are used in organic chemistry to denote specific configurations of a chiral center.
- the compound of the present invention can exist as a hydrate, or as a solvate, wherein the compound of the present invention contains a polar solvent, in particular water, methanol or ethanol for example as a structural element of the crystal lattice of the compound.
- a polar solvent in particular water, methanol or ethanol for example as a structural element of the crystal lattice of the compound.
- the amount of the polar solvent, in particular water may exist in a stoichiometric or non-stoichiometric ratio.
- the present invention includes all possible crystalline forms, or polymorphs, of the compound of the present invention, either as a single polymorph, or as a mixture of more than one polymorphs, in any ratio.
- substituents or “optionally” means an element may be, but is not necessarily, present in a corresponding situation or condition.
- the term comprises an example wherein a substituent is or is not present, and also comprises an example which is substituted with one or more substituents.
- substituted means that one or more (e.g., one, two, three, or four) hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- the expression “optionally substituted” covers situations where a compound is substituted with one or more substituents, and when the expression “optionally substituted” refers to a situation where a compound is substituted with multiple substituents, the substituents may be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from oxygen (O), nitrogen (N), and sulfur (S), and such saturated, unsaturated or aromatic ring may further form a ring with the group being substituted.
- substituents may be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from oxygen (O), nitrogen (N), and sulfur (S), and such saturated, unsaturated or aromatic ring may further form a ring with the group being substituted.
- substituents may be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from oxygen (O), nitrogen (N), and sulfur (S), and such saturated, unsaturated
- alkyl refers to an unbranched or branched, chain or cyclic, saturated, monovalent hydrocarbon residue, which preferably contains 1 to 14 carbon atoms (C 1-14 alkyl), more preferably contains 1 to 10 carbon atoms (C 1-10 alkyl), more preferably contains 1 to 6 carbon atoms (C 1-6 alkyl), and particularly preferably contains 1 to 4 carbon atoms (C 1-4 alkyl).
- alkyl group examples include, but are not limited to, lower alkyl groups including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl (e.g., hept-4-yl) and octyl.
- lower alkyl groups including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl (e.g., hept-4-yl) and octyl.
- cycloalkyl refers to a saturated, non-aromatic, monocyclic or polycyclic (such as bicyclic) hydrocarbon ring. When a cycloalkyl comprises two or more rings, the rings can be fused together. In its ring, a cycloalkyl group may contain 3 to 10 atoms (C 3-10 cycloalkyl), preferably 3 to 8 ring atoms (C 3-8 cycloalkyl), more preferably 3 to 6 ring atoms (C 3-6 cycloalkyl), and particularly preferably 3 to 4 ring atoms (C 3-4 cycloalkyl).
- the cycloalkyl group includes, but is not limited to monocycles such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicycicles, including spiro, fused, or bridged systems (such as bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl or bicyclo[5.2.0]nonanyl, decahydronaphthalenyl, etc.), optionally substituted with 1 or more (such as 1 to 3) suitable substituents.
- monocycles such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicycicles, including spiro, fused,
- alkenyl refers to a hydrocarbon residue having 2 to 10 carbon atoms and having one or two olefinic double bonds, and it preferably contains 2-8 carbon atoms (C 2-8 alkenyl), more preferably contains 2 to 6 carbon atoms (C 2-6 alkenyl), and particularly preferably contains 2 to 4 carbon atoms (C 2-4 alkenyl).
- alkenyl group examples include vinyl, 1-propenyl, 2-propenyl or 2-butenyl, etc.
- alkynyl refers to an unbranched or branched hydrocarbon chain group having 2 to 10 carbon atoms (C 2-10 alkynyl), and having one or two triple bonds, and it preferably contains 2-8 carbon atoms (C 2-8 alkynyl), more preferably contains 2 to 6 carbon atoms (C 2-6 alkynyl), and particularly preferably contains 2 to 4 carbon atoms (C 2-4 alkynyl).
- Examples of an alkynyl group are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.
- amino represents —NH 2
- alkylamino represents —NR′R′′, wherein R and R′′ are the same or different, and are H or an alkyl or cycloalkyl group as defined above.
- alkoxy represents —O-alkyl, wherein alkyl is as defined above (e.g., C 1-14 alkyl, C 1-10 alkyl, C 1-6 alkyl, or C 1-4 alkyl), such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy, etc., as well as isomers thereof.
- halogen refers to fluorine, chlorine, bromine or iodine.
- haloalkyl refers to the alkyl group as defined above, wherein 1, 2, 3, or more hydrogen atoms are replaced with halogens.
- Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl.
- haloalkoxy refers to the alkoxy group as defined above, wherein 1, 2, 3, or more hydrogen atoms are replaced with halogens.
- acyl represents a group of formula —C( ⁇ O)R, wherein R is hydrogen or an alkyl group as defined above (e.g., C 1-14 alkyl, C 1-10 alkyl, C 1-6 alkyl, or C 1-4 alkyl).
- alkylcarbonyl represents a group of formula —C( ⁇ O)R, wherein R is an alkyl group as defined above (e.g., C 1-14 alkyl, C 1-10 alkyl, C 1-6 alkyl, or C 1-4 alkyl).
- the term “amido” represents a group of formula —NC( ⁇ O)R′R′′, wherein R and R′ are the same or different, and are hydrogen or an alkyl group as defined above (e.g., C 1-14 alkyl, C 1-10 alkyl, C 1-6 alkyl, or C 1-4 alkyl).
- hydroxyalkyl represents a group of formula —R—OH, wherein R is an alkylene group.
- alkylene refers to a divalent, saturated, straight hydrocarbon group containing 1 to 10 carbon atoms (C 1-10 alkylene), more preferably 1 to 6 carbon atoms (C 1-6 alkylene), and particularly preferably 1 to 4 carbon atoms (C 1-4 alkylene), or a branched, saturated, divalent hydrocarbon group containing 3-10 carbon atoms (C 3-10 alkylene), more preferably 3-8 carbon atoms (C 3-8 alkylene), and particularly preferably 3-5 carbon atoms (C 3-5 alkylene).
- Examples of an alkylene group include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, butylene and 2-ethylbutylene, etc.
- aryl refers to a group having at least one aromatic ring, i.e., having a conjugated i-electron system, and includes a monocyclic aryl group, and a bicyclic aryl group. It contains 6-14 carbon atoms (C 6-14 aryl), such as phenyl and naphthyl, etc.
- Optionally substituted aryl includes an aryl group substituted with multiple substituents, and the substituents can be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S.
- the aryl group preferably includes the following groups:
- aralkyl represents group R′R′′—, wherein R′ is an aryl group as defined herein, and R′′ is an alkylene group as defined herein. It is to be understood that the point of attachment of the aralkyl moiety would be at the alkylene group. Normally, the aryl group may contain 6-14 carbon atoms, and the alkyl group may contain 1-6 carbon atoms. Exemplary aralkyl includes, but is not limited to benzyl, 4-fulorobenzyl, phenylethyl, phenylpropyl, and phenylbutyl.
- aryloxy represents —O—R, and R is an aryl group as defined above.
- arylcarbonyl represents a group of formula —C( ⁇ O)Ar, wherein Ar is an aryl group as defined above.
- heterocyclyl refers to a 3-16 membered saturated or unsaturated ring containing 1-4 (e.g., one, two, three, or four) heteroatoms selected from N, O, S, and P, with the remaining atoms as carbon atoms.
- a 3-10 membered heterocyclyl is a group having 3-10 carbon atoms as well as heteroatoms in its rings, such as, but not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, pyrrolidinonyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl.
- heteroaryl refers to a cyclic aromatic group having 1 to 3 heteroatoms selected from N, O and S atoms as ring atoms, with the remaining ring atoms as carbon atoms, wherein the ring is a 4-16 membered monocycle or fused ring, preferably a 5-12 membered monocycle or fused ring, or a 5-8 membered monocycle or fused ring.
- heteroaryl group examples include, but are not limited to, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrrolyl, pyrazolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, pyridazinyl, phthalazinyl, phthalazin-1-(2H)-1-yl, pyrido[3,2-d]pyridazin-5(6H)-8-yl, triazinyl, etc., as well as benzo derivatives thereof.
- heteroarylcarbonyl is defined similar to the definition of “arylcarbonyl group”, and represents a group of formula —C( ⁇ O)R, wherein R is a heteroaryl group as defined above.
- heteroaryloxy represents a group of formula heteroaryl-O—, wherein the heteroaryl group is as defined above.
- sulfonamido represents a group of formula —SO 2 NR′R′′, wherein R and R′ are the same or different, and are each independently hydrogen or an alkyl or cycloalkyl group as defined above.
- carboxyl represents a group of formula —COOH
- carboxylate represents —COOR, wherein R each independently represents an alkyl group as defined above.
- a group, or an atom, or a radical each includes a group, or an atom, or a radical with substitution of an isotope
- “hydrogen” includes H, 2 H (deuterium), or 3 H (tritium);
- a C 1-14 alkyl group includes an alkyl group wherein one or more, or all of the carbon atoms are 12 C, 13 C, or 14 C; and further exemplary examples include isotopes of N, P, or O.
- the term “pharmaceutically acceptable carrier” refers to inactive ingredients in a pharmaceutical composition or a pharmaceutical preparation that do not cause significant irritation and do not interfere with the nature of the biologically active compounds applied in an organism, and it includes a diluent, adjuvant, excipient or equivalent pharmaceutically acceptable medium administered together with a therapeutic agent.
- excipient refers to a substance for the preparation of a pharmaceutical composition, and it is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes various excipients suitable for veterinary use as well as human pharmaceutical use.
- the pharmaceutically acceptable carrier which can be employed in the pharmaceutical composition of the present invention includes, but is not limited to sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. Physiological salines as well as aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in e.g. Remington's Pharmaceutical Sciences (1990).
- formulation shall include solid, semi-solid, liquid, or gas formulations.
- the formulation or dosage form includes, but is not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, salves, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
- the compound of the present invention may be prepared as different formulations.
- the unit dosage range of the compound of the present invention is 0.1-1000 mg, preferred unit dosage range is 1-800 mg, more preferred unit dosage range is 10-600 mg, particularly preferred unit dosage range is 50-450 mg, and the most preferred unit dosage range is 100-300 mg.
- the formulation or dosage form of the present invention may contain a single or multiple unit dosage of the compound of the present invention.
- the compound of the present invention is preferably for oral administration.
- other administration routes may be employed or even preferred, such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, or transdermal administration, or administration via buccal, nasal, transmucosal, topical, route, as an ophthalmic formulation, or via inhalation.
- Transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine.
- the compound of the present invention may also be administered by the percutaneous, intramuscular, intranasal or intrarectal route in particular circumstances.
- the route of administration may be varied in any way, depending on the physical properties of the drugs, the convenience of the patient and the caregiver, and other relevant conditions (Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).
- the present invention provides use of the compound of the present invention for simultaneous, separate or sequential administration in combination with an additional therapeutic agent (such as an additional anti-cancer/anti-tumor agent, or an additional anti-viral agent).
- an additional therapeutic agent such as an additional anti-cancer/anti-tumor agent, or an additional anti-viral agent.
- the dosage range of the compound of the present invention or a product comprising the same is 0.1-1000 mg/kg body weight per day, preferred dosage range is 1-800 mg/kg body weight per day, preferred dosage range is 10-600 mg/kg body weight per day, particularly preferred dosage range is 100-400 mg/kg body weight per day, and most preferred dosage range is 120-250 mg/kg body weight per day.
- the exact dosage required for treating a patient may be determined by a physician in view of the stage and severity of the disease as well as patient's specific need and response.
- treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- the term “mammal” includes a human or non-human animal.
- An exemplary human subject includes a human subject having a disease or disorder (such as one described herein) (referred to as a patient), or a normal subject.
- the term “non-human animal” as used herein includes non-human primates, livestock and/or domesticated animals, such as sheep, dog, cat, cow, pig and the like.
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to ⁇ 60° C. A solution of phenol (940 mg, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine ethyl ester hydrochloride (1.53 g, 10 mmol) was added.
- Compound C2 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine benzyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C3 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine phenyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to ⁇ 60° C. A solution of 4-fluorophenol (1.12 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine isopropyl ester hydrochloride (1.53 g, 10 mmol) was added.
- Compound C5 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-chlorophenol, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C6 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-bromophenol, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to ⁇ 60° C. A solution of phenol (1.12 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and 2-methyl-alanine isopropyl ester hydrochloride (1.82 g, 10 mmol) was added.
- Compound C8 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and Compound A as starting materials.
- Compound C9 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and 1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-5-fluorocytosine as starting materials.
- Compound C10 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and (2R,3S,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ol as starting materials.
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to ⁇ 60° C. A solution of sesamol (1.38 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine isopropyl ester hydrochloride (1.53 g, 10 mmol) was added.
- the mixture of the diastereomers obtained in the previous step was separated by preparative HPLC using the following separation conditions: octadecyl bonded silica gel was used as filler (20 ⁇ 250 mm, 5 ⁇ m), column temperature was 40° C., flow rate was 10.0 mL/min, detection wavelength was 220 nm, mobile phase A was water (neutral), mobile phase B was methanol, and linear gradient elution was performed.
- the first main peak was collected, and freeze-dried to obtain (S)-isopropyl 2-(((R)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(benzo[d][1,3]dioxol-5-yloxy)phosphoryl)amino)propanoate (C13), 17 mg; and the second main peak was collected, and freeze-dried to obtain (S)-isopropyl 2-(((S)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(benzo[d][1,3]dioxol-5-yloxy)phospho
- Compound C15 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine 4-fluorobenzyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C16 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 5-hydroxy-2,3-dihydrobenzo[1,4]dioxine, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C17 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-hydroxy-7-fluoro-2,3-dihydrobenzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C18 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 6-hydroxy-2,3-dihydrobenzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- Compound C19 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 6-hydroxy-benzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- This experimental example was used for the evaluation of the effectiveness of the compounds of the present invention in inhibiting the proliferation of human gastric cancer NCI-N87, colorectal cancer HCT-116, colorectal cancer HCT-15, and pancreatic cancer BxPC-3 cell lines.
- the tumor cell lines employed in the present experiment were gastric cancer cell NCI-N87 (obtained from Guangzhou Jennio Biological Technology Co., Ltd.), colorectal cancer cell HCT-116 (obtained from Chengdu Center for Safety Evaluation of Drugs), colorectal cancer cell HCT-15 and pancreatic cancer cell BxPC-3 (both obtained from ATCC, US).
- the above cell lines were cultured as a monolayer in vitro, and the culture conditions were as follows. Each of the cell lines is cultured in a corresponding culture medium (RPMI-1640, IMDM and L-15 culture medium (manufacturer: Gibco)) supplemented with 10% heat inactivated Fetal Bovine Serum (manufacturer: Sigma), in an incubator at 37° C. and 5% CO 2 . The cells were subcultured by treatment with trypsin-EDTA digestion.
- a blank group For each type of tumor cells, a blank group, a vehicle group (containing 1 ⁇ DMSO) and 8 groups with a test compound at concentrations of 5 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1000 nM, 5000 nM, and 10000 nM (with each concentration in triplicate) were set.
- the experiment was performed according to a CCK-8 method as described below. Cancer cells to be tested were seeded in a 96-well culture plate at a concentration of 5 ⁇ 10 ⁇ 10 4 /mL (100 ⁇ L/well), followed by incubation at 37° C. and 5% CO 2 for 24 h. The medium was discarded, and incubation solutions with different drug concentrations (200 ⁇ L) were respectively added to each well, and the cells were further incubated for 72 h. After the incubation, a CCK-8 solution (20 ⁇ L/well) was added to each well to be tested, and the incubation was continued for 4 h in the incubator. OD values at two wavelengths (Detection wavelength: 450 nm, and reference wavelength: 650 nm) were determined on a multifunctional fully-automatic microplate reader.
- the inhibitory rate of tumor cell growth was calculated according to the following formula:
- Inhibitory rate [(OD vehicle ⁇ OD blank ) ⁇ (OD drug ⁇ OD blank )]/(OD vehicle ⁇ OD blank )*100%
- FIG. 1 shows that the compound of Example 8 (C8) has potent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-116, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3 at the above 8 concentrations.
- IC 50 values of example compounds of the present invention for each type of cancer cells are shown in table 1-1 to 1-4.
- the IC 50 values of the compounds of the present invention were in the range of 0.1-1 ⁇ M for gastric cancer cell NCI-N87, in the range of 0.1-1 ⁇ M for colorectal cancer cell HCT-116, in the range of 0.5-10 ⁇ M for colorectal cancer cell line HCT-15, and in the range of 0.1-5 ⁇ M for pancreatic cancer cell BxPC-3.
- the compounds of the present invention have inhibitory activity on tumor cells.
- the compound of Example 8 (C8) of the present invention has a potent anti-tumor effect in vitro, and has excellent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-116, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3.
- the compounds of Examples 2, 14 and 15 each have excellent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3.
- the compounds of Examples 16, 17 and 19 have excellent inhibitory effects on gastric cancer cell NCI-N87 and pancreatic cancer cell BxPC-3.
- the compound of Example 13 has an excellent inhibitory effect on gastric cancer cell NCI-N87
- the compound of Example 18 has an excellent inhibitory effect on pancreatic cancer cell BxPC-3.
- This experimental example was used for the evaluation of the effectiveness of the compounds of the present invention in inhibiting the proliferation of a subcutaneous xenograft of human tumor cells via various routes of administration.
- the present experimental example investigated variations in tumor volume and body weight of mice with subcutaneous xenografts of human colorectal cancer cell line HCT-116 and gastric cancer cell line NCI-N87 after compound C8 was administered via various routes, so as to determine the pharmacological efficacy and toxicity of each test sample on mice bearing a tumor of colorectal cancer cell HCT-116 or gastric cancer cell NCI-N87.
- Gastric cancer cell NCI-N87 and colorectal cancer cell HCT-116 were cultured as a monolayer in vitro, and the culture conditions were RPMI-1640 culture medium supplemented with 10% heat inactivated Fetal Bovine Serum, and incubation in an incubator at 37° C. and 5% CO 2 . The cells were subcultured by treatment with trypsin-EDTA digestion.
- the tumor cells were respectively inoculated into BALB/c nude mice (SPF grade, female, 16-18 g per mouse, about 6 to 8 weeks old, Beijing Vital River Laboratory Animal Technology Co., Ltd.).
- Each nude mouse was inoculated with about 2.5 ⁇ 10 6 HCT-116 tumor cells or about 3 ⁇ 10 6 NCI-N87 tumor cells (suspended in 0.1 ml PBS) subcutaneously into the underarm of the right flank. After the inoculated tumor reached a size in the range of about 100-200 mm 3 , nude mice bearing a tumor that is too small (smaller than 100 mm 3 ) or too big (bigger than 200 mm 3 ) were removed from the study, and the remaining ones were randomized into groups.
- SE- ⁇ -CD Sulfobutyl ether- ⁇ -cyclodextrin
- test compound An appropriate amount of the test compound was weighted, and added in DMSO.
- the resultant solution was vortexed to uniformity, and the 10% solution of SE- ⁇ -CD was added according to the desired concentration.
- the solution was vortexed to uniformity, and the final concentration of DMSO was adjusted to 5%.
- a gemcitabine injection (a positive control) was directly diluted to the desired concentration with physiological saline.
- a 10% solution of SE- ⁇ -CD containing 5% DMSO was prepared as a vehicle control.
- mice bearing a tumor having a volume of about 100-200 mm 3 were selected, and randomized into 5 groups (8 mice per group).
- the dosing volume was 10 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed twice a week for 3 weeks.
- the tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- the anti-tumor effect was evaluated by the tumor growth inhibition (TGI) (%).
- TGI (%) [1 ⁇ ( V T-end ⁇ V T-start )/( V C-end ⁇ V C-start )]*100%
- V T-end the mean value of tumor volume of a treatment group at the end of the test
- V T-start the mean value of tumor volume of a treatment group at the beginning of the test
- V C-end the mean value of tumor volume of a vehicle group at the end of the test
- V C-start the mean value of tumor volume of a vehicle group at the beginning of the test.
- pancreatic cancer cell BxPC-3 was cultured as a monolayer in vitro, and inoculated, and the animals were randomized into groups.
- SE- ⁇ -CD Sulfobutyl ether- ⁇ -cyclodextrin
- mice bearing a tumor having a volume of 100-200 mm 3 were selected, and randomized into 14 groups (7 mice per group).
- the dosing volume was 20 mL/kg, and the administration (intravenous administration (i.v.)) was performed once every 3 days, for 4 times in total.
- the tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection.
- pancreatic cancer cell BxPC-3 was cultured as a monolayer in vitro, and inoculated; the animals were randomized into groups; and samples were prepared.
- mice bearing a tumor having a volume of 80-250 mm 3 were selected, and randomized into 6 groups (8 mice per group).
- the dosing volume was 10 mL/kg.
- the tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- test results obtained by administrating twice a week for 3 weeks in total are shown in table 7-1.
- test results obtained by administrating intravenous administration (i.v.) or oral administration (p.o.) once a week for 3 weeks are shown in table 7-2.
- compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection. Moreover, compound C8 exhibits excellent oral bioavailability. As oral administration is an administration route more acceptable to a patient, compound C8 of the present invention has improved tolerability in a patient.
- pancreatic cancer cell Capan-1 was cultured as a monolayer in vitro, and inoculated, and the animals were randomized into groups.
- mice bearing a tumor having a volume of 100-200 mm 3 were selected, and randomized into 7 groups (7 mice per group).
- the dosing volume was 20 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed once every 3 days, for 6 times in total.
- the tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell Capan-1 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection. Moreover, the effects achieved by oral and intravenous administration of compound C8 were better than that achieved by gemcitabine administrated in a dose three times higher than that of C8.
- mice bearing a tumor having a volume of 100-200 mm 3 were selected, and randomized into 4 groups (6 mice per group).
- the dosing volume was 10 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed once every 3 days, for 6 times in total.
- the tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell Capan-1 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection.
- mice Normal Male and female Kunming mice (SPF grade, obtained from Laboratory Animal Center in Sichuan Academy of Chinese Medicine Science) were randomized by weight into groups.
- the test compound and vehicle control were formulated according to Experimental example 2.
- the dosage volume was 10 mL/kg, and the administration was performed by oral gavage, once per day for 7 consecutive days.
- mice passing the quarantine control were randomized into 4 groups (3 mice/gender/group).
- the test compound and vehicle control were formulated according to Experimental example 2.
- the dosage volume was 10 mL/kg, and the specific dosages were as shown in table 11.
- the mortality, appearance, behavior, mental status, secretion and excreta etc. of the animals were observed every day for 7 consecutive days after the administration, and the animals were anatomized on day 8.
- Dosage Dosage Group Drug (mg/kg) ( ⁇ mol/kg) Animal number 1 Physiological saline 0 0 3 male + 3 female 2 Vehicle control 0 0 3 male + 3 female 3 Compound C8 60.9 115.38 3 male + 3 female 4 Compound A 20 76.92 3 male + 3 female
- the animals from the group treated with compound A exhibited symptoms such as a hunched stance and weight loss, etc. on day 8, while no relevant abnormalities were observed in group 3 (the group treated with compound C8).
- the body weight of the animals treated with compound A decreased gradually, and on day 8, the body weight of the female and male mice decreased by 20.2% and 18.1%, respectively; while the body weight of the animals from the group treated with compound C8 increased gradually, and on day 8, the body weight of the female and male mice increased by 13.1% and 26.7%, respectively.
- the leukocyte count in the female and male animals from the group treated with compound C8 decreased by 45% and 49%, respectively, and the platelet count decreased by 43% and 39%, respectively; while the leukocyte count in the female and male animals from the group treated with compound A decreased by 83% and 87%, respectively, and the platelet count decreased by 71% and 77%, respectively.
- the compounds prepared in the present invention whether administered intravenously or orally, all achieved excellent anti-tumor effects, and tumors showed complete regression or partial regression. More surprisingly, the pharmacological effects achieved by administering the compounds of the present invention via two different routes were all better than that of the gemcitabine injection (tumors showed no or less regression in the group treated with the gemcitabine injection), and the defect of poor oral bioavailability of gemcitabine was completely overcome.
- the body weight of the animals in the group treated with the gemcitabine injection decreased during the experiment, indicating that the injection caused certain damages to the test animals; while the body weight of animals in the groups treated with the compounds in the examples of the present invention increased during the experiment, indicating the compounds of the present invention have better tolerability and safety profiles in the animals in different groups.
- the 4′-thio-2′-fluoronucleoside compounds of the present invention have excellent pharmacological effects.
- the compounds of the present invention have increased lipid solubility, improved bioavailability, reduced irritation, improved absorption, and no issues in metabolic rate.
- the most critical breakthroughs of the compounds of the compounds of the present invention are significantly reduced toxicity, improved safety profile, and efficacy achieved through various routes of administration (intravenous or oral administration).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present application relates to a method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a 4′-thionucleoside compound or a pharmaceutically acceptable salt, ester, hydrate, solvate thereof, or racemate thereof, or a mixture thereof.
Description
- The present application is a continuation of U.S. application Ser. No. 15/558,620, filed 15 Sep. 2017, which is a national stage filing under 35 U.S.C. § 371 of PCT/CN2016/077519, filed on 28 Mar. 2016, and claims priority to Chinese patent application 201510157772.0, filed 3 Apr. 2015. Each application is incorporated by reference in its entirety.
- The present invention relates to a novel 4′-thionucleoside compound, to a preparation method thereof, to a pharmaceutical composition comprising the compound, and to use thereof. Specifically, the present invention relates to a phosphamide derivative of a 4′-thionucleoside, to a preparation method thereof, to a pharmaceutical composition comprising the derivative, and to use thereof for the prevention or treatment of an abnormal cell proliferative disease (e.g., tumor, cancer and related disorders) or a viral infectious disease.
- A natural nucleoside is a glycoside comprising a ribose or a deoxyribose and a base (such as adenine, thymine, guanine, cytosine or uracil), and is an important component of DNA and RNA. Artificially synthesized nucleoside analogues are an important class of chemotherapeutic drugs for tumor, and are referred to as antimetabolites. The effect thereof is mainly achieved by affecting enzymatic system in tumor cells, thereby inhibiting the synthesis of DNA and RNA. According to statistics from WHO, cancer is one of the leading causes of death worldwide. Moreover, drug resistance in cancer cells is ubiquitous, and it is urgently needed to develop new anti-cancer drugs for human health. As such, it is an arduous task in the pharmaceutical industry to develop safe and reliable anti-cancer drugs from various perspectives. Treatment employing an organ specific nucleoside prodrug represents one of the most promising therapeutic methods.
- Nucleoside drugs, such as gemcitabine, azacitidine, decitabine, cytarabine, fludarabine, cladribine, 6-azauridine, tiazofurine and atromide, etc., have been widely used for the treatment of various cancers. There are many nucleoside drugs that are currently at different stages of clinical development.
- Gemcitabine is a pyrimidine nucleoside analogue developed by Eli Lilly and Company in the US, and is an important nucleoside-based anticancer drug as a first-line therapeutic agent for advanced pancreatic cancer, advanced non-small cell lung cancer, localized or metastatic bladder cancer and metastatic breast cancer. It has a broad spectrum of anti-tumor activity, and is effective for a variety of additional solid tumors. Gemcitabine generally needs to be administered in combination with paclitaxel, cisplatin, and/or carboplatin. Gemcitabine has poor cell permeability, low bioavailability, and a short half-life in cells (between 32˜94 min), and thus must be continuously intravenously administered at a high dose (with a recommended dose of 1000 mg/m2), so as to maintain its effective blood drug concentration and toxicity to cancer cells. The dose-limiting toxicity induced by the high dose of gemcitabine employed affects clinical efficacy, and results in a series of side effects and safety issues, such as leukopenia, transaminase abnormalities, proteinuria, as well as nausea and vomiting, etc. In addition, gemcitabine has a number of shortcomings, including lack of tissue specificity which leads to high systemic toxic effects; rapid metabolism and a short plasma half-life; drug resistance in tumors; poor effects achieved through oral administration, common requirement of administration through intravenous injection, a high dosage and severe side effects; poor efficacy achieved when the drug is administered alone, and necessity of co-administration with another anti-cancer drug; etc.
- Gemcitabine has poor oral bioavailability, and thus generally needs to be administrated via intravenous injection. The poor oral bioavailability is a result of first-pass metabolism (see Shipley L A., et al., “Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs”. Drug Metabolism & Disposition. 20(6):849-55, 1992). In addition, when dosed orally, gemcitabine is implicated in causing adverse dose-limiting intestinal lesions characterized by moderate-to-marked loss of mucosal epithelium (atrophic enteropathy) throughout the entire length of the intestinal tract in mice given a single oral (gavage) gemcitabine dose of 167, 333, or 500 mg/kg (see Horton N D et al., “Toxicity of single-dose oral gemcitabine in mice”, American Association for Cancer Research, Poster Presentation, Orlando, Fla., Mar. 27-31, 2004). In a previous study performed on mice, no death or gastrointestinal toxicity was observed when a significant dose was administered intravenously.
- Moreover, gemcitabine, like other nucleoside drugs, is a hydrophilic compound, and thus cannot go through cellular membranes into cells via passive diffusion, but needs a specific transport protein to be delivered into tumor cells. Alteration in the nucleoside transport activity has been considered as an important cause of resistance to gemcitabine. Human equilibrative nucleoside transporter 1 (hENT1) is an important transport protein currently identified for the transportation of gemcitabine into tumor cells. As reduction of intracellular drug accumulation would likely result in decreased sensitivity to gemcitabine, scientists at Clavis Pharma, Norway, have synthesized a 5′-elaidic acid ester derivative of gemcitabine, CP-4126, which has significantly improved lipophilicity than that of gemcitabine. Studies show that CP-4126 can get into tumor cells independent of hENT1 transporter, and thus is expected to exhibit a better anti-tumor effect in tumor patients with a low expression of hENT1.
- 4′-thionucleoside refers to a nucleoside analogue with the oxygen atom in the furanose ring replaced by a sulfur atom. The synthetic route for 4′-thionucleosides is long and difficult, which greatly limits the study of such compounds. U.S. Pat. No. 6,147,058 discloses a 4′-thionucleoside compound which exhibit inhibitory activity in a colon cancer model in nude mice. This compound is shown to have a better effect in inhibiting tumor growth than that of gemcitabine (Cancer Let. 1999, 144, 177-182; Int. J. Cancer, 2005, 114, 1002-1009). U.S. Pat. No. 5,128,458 discloses a 2′,3′-dideoxy-4′-thioribonucleotides with good effects in the treatment of both a viral infectious disease (such as HIV, hepatitis B or C) and an abnormal cell proliferative disease.
- Although the 4′-thionucleoside compound has a better effect in inhibiting tumor growth, it also possesses similar shortcomings to those of gemcitabine, such as low oral bioavailability, fast metabolism, multiple adverse effects and drug resistance, etc.
- Resistance to 4′-thionucleoside drugs is a main reason for the short survival period of a patient. The major causes for the development of resistance include: 1) lack of corresponding transporter proteins on the surface of tumor cells, which prevents nucleoside drugs from efficiently passing through cellular membranes; 2) low efficiency of the conversion from the drug to the active species as a triphosphate; and 3) metabolism from the drug to an inactive species in the presence of an enzyme.
- Since 4′-thionucleoside drug can be quickly metabolized to an inactive species and lose activity, no 4′-thionucleoside drug is available for the treatment of cancers such as liver cancer to date.
- So far, problems encountered in the development of 4′-thionucleoside drugs make them difficult to be approved by authorities. A prodrug approach has been employed to overcome such problems. Now a lot of pharmaceutical companies are still working in developing methods for treating cancers by using other prodrugs (see G. Xu, H. L. McLeod, Clin. Cancer Res., 2001, 7, 3314-3324; M. Rooseboom, J. N. M. Commandeur, N. P. E. Vermeulen, Pharmacol. Rev., 2004, 56, 53-102; W. D. Wu, J. Sigmond, G. J. Peters, R. F. Borch, J. Med. Chem. 2007, 50, 3743-3746).
- Upon entry into a body, a nucleoside drug would firstly be phosphorylated to form an active metabolite, monophosphate, through the catalysis of a corresponding kinase, and the monophosphate is then converted to a triphosphate. Monophosphorylation of a nucleoside drug is often a rate-limiting step in the metabolism of the drug. Kinases catalyzing the monophosphorylation of a nucleoside in human bodies (thymidine kinase (TK), deoxycytidine kinase (dCK), deoxyguanosine kinase (dGK) and adenosine kinase (AK)) have a limited affinity to nucleosides, and the kinase activity is liable to be inhibited by nucleotide monophosphate (NA-MP). These both limit the in vivo activation of nucleoside drugs, and affect the exhibition of drug activity. To address this issue, researchers have attempted to modify nucleoside drugs through phosphorylation, so as to obtain corresponding phosphates or phosphamide (ChemMedChem, 2009, 4, 1779-1791).
- However, in development of a drug through modification, it is difficult to determine whether the modified drug can successfully release the parent drug after entering the body, since the parent drug is different from case to case, and the modified drug often has reduced or no efficacy, or result in new side effects. As such, in years of research, 4′-thionucleoside compounds currently available still have druggability issues, which are difficult to overcome. Today, after gemcitabine is on the market for many years, there is still no 4′-thionucleoside compound approved for clinical application.
- According to an aspect of the present invention, a 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I) is provided,
- wherein:
- X is hydrogen, C1-6 alkyl, halogen, N3, OH, CN or SH;
- Y is oxygen or sulfur;
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, and optionally substituted C1-10 acyl;
- Q is a pyrimidine base or a purine base having the following structure:
- R5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl and optionally substituted cycloalkyl; and
- Z is hydrogen, optionally substituted C1-10 alkyl or halogen;
- the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- According to another aspect of the present invention, a pharmaceutical composition or a pharmaceutical formulation is provided, wherein the pharmaceutical composition or the pharmaceutical formulation comprises the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof, as an active ingredient, and a pharmaceutically acceptable carrier, adjuvant, excipient or equivalent pharmaceutically acceptable medium. The pharmaceutical composition or the pharmaceutical formulation can be in a form suitable for administration to a mammal, including a solid preparation, a semi-solid preparation, a liquid preparation, and a gas preparation, etc.
- According to a further aspect of the present invention, a use of the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I) in the manufacture of a medicament for the prevention or treatment of an abnormal cell proliferative disease or a viral infectious disease in a mammal is provided. The abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof. Optionally, the medicament further comprises an additional anti-tumour agent.
- According to a further aspect of the present invention, a method for the prevention or treatment of an abnormal cell proliferative disease and/or a viral infectious disease in a mammal is provided, wherein the method comprises administering to the mammal an effective amount of the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof. The abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof in a mammal.
- According to a further aspect of the present invention, the above 4′-thio-2′-fluoronucleoside phosphamide compound as represent by Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof for the prevention or treatment of an abnormal cell proliferative disease and/or a viral infectious disease in a mammal is provided. The abnormal cell proliferative disease in a mammal is e.g. cancer and/or tumor and related disorders thereof in a mammal.
- According to a further aspect of the present invention, a method for preparing the above compound as represent by Formula (I) is provided, wherein the method comprises the following steps:
- wherein each of the groups is as defined above, and step 1 is preferably performed in the presence of POCl3.
- The present invention will now be described in more detail with reference to the accompanying drawing, wherein:
-
FIG. 1 shows the effects of the compound of Example 8 (C8) on four different tumor cells at various concentrations. - Compound
- An embodiment of the present invention provides a compound of Formula (I),
- wherein:
- X is hydrogen, C1-6 alkyl, halogen, N3, OH, CN or SH;
- Y is oxygen or sulfur;
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, and optionally substituted C1-10 acyl;
- Q is a pyrimidine base or a purine base having the following structure:
- R5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl and optionally substituted cycloalkyl; and
- Z is hydrogen, optionally substituted C1-10 alkyl or halogen;
- the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- Another embodiment of the present invention provides the above compound of Formula (I), wherein:
- Q is a pyrimidine base having the following structure:
- and
- Z is hydrogen, methyl, or halogen;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein
- Q is a pyrimidine base having a structure as shown below:
- and
- Z is hydrogen, methyl, or halogen;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein:
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- Q is cytosine having the following structural formula:
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein Q is selected from
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein X is hydrogen or halogen, and the halogen is fluorine, chlorine, bromine or iodine.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein Y is oxygen.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, and optionally substituted aryl (preferably optionally substituted C6-14 aryl), the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, C1-6 alkyl, and C6-14 aryl. Most preferably, R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, phenyl, benzyl, and 4-fluorobenzyl.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein R3 is selected from the group consisting of optionally substituted aryl, preferably optionally substituted C6-14 aryl, more preferably optionally substituted phenyl, the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, C1-6 alkyl, and C1-6 alkoxy, and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 (e.g. 1, 2, or 3) O. Most preferably, R3 has a structure as shown below:
- A further embodiment of the present invention provides the above compound of Formula (I), wherein R4 is hydrogen.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein R5 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted C1-10 alkyl (e.g. hept-4-yl).
- A further embodiment of the present invention provides the above compound of Formula (I), wherein Z is hydrogen, methyl, fluorine or chlorine.
- The present invention encompasses the above compound of Formula (I) obtained by any combination of groups in the definitions of the above-described various embodiments, and would not be constrained by each individual embodiment.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein Q is
- X is hydrogen, C1-6 alkyl, halogen, N3, OH, CN or SH;
- Y is oxygen or sulfur;
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, and optionally substituted C1-10 acyl;
- R5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl and optionally substituted cycloalkyl; and
- Z is hydrogen, methyl or halogen;
- the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be independent from each other, or be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), wherein Q is cytosine having the following structural formula:
- X is hydrogen, C1-6 alkyl, halogen, N3, OH, CN or SH;
- Y is oxygen or sulfur;
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, and optionally substituted C1-10 acyl;
- R5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl and optionally substituted cycloalkyl; and
- Z is hydrogen, optionally substituted C1-10 alkyl or halogen;
- the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I),
- wherein:
- X is hydrogen, C1-6 alkyl, halogen, N3, OH, CN or SH;
- Y is oxygen or sulfur;
- R1, R2, R6, and R7 are each independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl, optionally substituted cycloalkyl, and optionally substituted aryl, wherein R2 and R6 can be connected to form a 3-8 membered carbocyclic ring which may contain 0-3 heteroatoms selected from N, O, and S, and may be a saturated, unsaturated, or aromatic ring;
- R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, and optionally substituted C1-10 acyl;
- Q is a purine base having the following structure:
- R5 at each occurrence is independently selected from the group consisting of hydrogen, optionally substituted C1-10 alkyl and optionally substituted cycloalkyl; and
- Z is hydrogen, methyl or halogen;
- the above expression “optionally substituted” means unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, alkoxy, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxyalkyl, amido, sulfonamido, cyano, nitro, nitroso, azido, aldehyde, alkynyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxy, heteroaryl, heteroaryloxy, acyl, carboxyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, and carboxylate; and the substituents can be independent from each other, or be connected to each other to form a 3-8 membered saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S;
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the above compound of Formula (I), which is a 4′-thio-2,2-difluoronucleoside phosphamide compound (i.e., X in Formula (I) is F), and Q is a pyrimidine group in its definition, and the remaining substituents are each as defined as above.
- A further embodiment of the present invention provides the above compound of Formula (I), which is a 4′-thio-2,2-difluoronucleoside phosphamide compound (i.e., X in Formula (I) is F), and Q is a cytosine group in its definition, and the remaining substituents are each as defined as above.
- The preferred compounds of the present invention are as follows:
- or a pharmaceutically acceptable salt, ester, solvate, hydrate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- In extensive research, structural modifications and activity screening are made to the 4′-thio-2′-fluoronucleoside compound in the present application, and the compound with a specific phosphamide substituent at position 5 of the present invention is obtained. The compound of the present invention has superior pharmaceutical efficacy, including an anti-tumor/anti-cancer effect and an effect on a viral infectious disease, as well as increased liposolubility, improved bioavailability, reduced irritation, and improved absorption. Issues in metabolic rate present in existing drugs are addressed, toxicity is significantly reduced, and safety profile is improved. The pharmacological effect can be achieved through various administration routes.
- The compound of Formula (I) described in the present invention refers to all the compounds covered by Formula (I), pharmaceutically acceptable salts, esters, hydrates, solvates, isomers thereof, or any crystalline form or racemate thereof, or metabolites thereof, or mixtures thereof.
- A further embodiment of the present invention provides a pharmaceutical composition, comprising the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof, as an active ingredient, and a pharmaceutically acceptable carrier, adjuvant, excipient or equivalent pharmaceutically acceptable medium.
- The pharmaceutical composition may comprise the compound of Formula (I) in a unit dose ranging from 0.1-1000 mg, preferably 1-800 mg, more preferably 10-600 mg, particularly preferably 50-450 mg, and most preferably 100-300 mg.
- The pharmaceutical composition may be in a form of e.g., a solid, semi-solid, liquid, or gas preparation. In particular, the solid preparation is e.g. a tablet, capsule, powder, granule, or suppository, etc.; the liquid preparation is e.g. a solution, suspension or injection. The composition can also be a preparation such as liposome, and microsphere. Particularly, the pharmaceutical composition is in a dosage form suitable for oral administration.
- The pharmaceutical composition can be in a form of a single dose unit or multiple dose units, each of the dose unit comprises a suitable amount of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, or any crystalline form or racemate thereof, or a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides a use of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of an abnormal cell proliferative disease or a viral infectious disease in a mammal. The medicament may comprise the compound of Formula (I) in a unit dose ranging from 0.1-1000 mg, preferably 1-800 mg, more preferably 10-600 mg, particularly preferably 50-450 mg, and most preferably 100-300 mg.
- A further embodiment of the present invention provides a method for the treatment or prevention of an abnormal cell proliferative disease or a viral infectious disease in a mammal, wherein the method comprises administering to the mammal an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof.
- A further embodiment of the present invention provides the compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof for the treatment or prevention of an abnormal cell proliferative disease or a viral infectious disease in a mammal.
- The abnormal cell proliferative disease or the viral infectious disease is e.g. cancer and/or tumor and related disorders thereof. The cancer and/or tumor include(s) tumors and/or cancers and related disorders in esophagus, stomach, intestine, rectum, mouth, pharynx, larynx, lung, colon, breast, uterus, endometrium, ovary, prostate, testis, bladder, kidney, liver, pancreas, bone, connective tissue, skin, eye, brain and central nervous system, as well as thyroid cancer, leukemia, Hodgkin disease, lymphoma and myeloma.
- The compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof can be administered in combination with an additional anti-tumour agent for the prevention or treatment of an abnormal cell proliferative disease (such as cancer and/or tumor and related disorders thereof) in a mammal. The additional anti-tumor agent refers to a substance with activity against tumor/cancer and related disorders thereof, and includes but is not limited to erlotinib or cisplatin.
- The compound of Formula (I), or a pharmaceutically acceptable salt, ester, hydrate, solvate, isomer thereof, any crystalline form or racemate thereof, a metabolite thereof, or a mixture thereof can be administered in combination with an additional anti-viral agent for the prevention or treatment of a viral infectious disease. The additional anti-viral agent includes but is not limited to lamivudine, entecavir, nevirapine or stavudine.
- The expression “administered in combination” encompasses two or more drugs are administered simultaneously, sequentially, or alternatively, and particularly encompasses two or more drugs are prepared into one or more dose units, so as to obtain a pharmaceutical product suitable for administration in combination, which is administered to a mammal in need thereof.
- A further embodiment of the present invention provides a method for preparing the compound of Formula (I), comprising the following steps:
- wherein each of the groups is as defined above, and step 1 is preferably performed in the presence of POCl3.
- Unless otherwise defined in the context, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by a person skilled in the art. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques which would be apparent to a person skilled in the art. While it is believed that most of the following terms will be readily understood by a person skilled in the art, the following definitions are nevertheless put forth to better illustrate the present invention.
- The expression “as defined above” refers to the first and/or the broadest definition provided in the application, as well as scenarios suitable in the context.
- The terms “contain”, “include”, “comprise”, “have”, or “relate to”, as well as other variations used herein are inclusive or open-ended, and do not exclude additional, unrecited elements or method steps.
- As used herein, the term “compound of the present invention” generally refers to the scope of compounds defined by above Formula (I), or pharmaceutically acceptable salts, esters, hydrates, solvates, isomers thereof, any crystalline form or racemate thereof, metabolites thereof, or mixtures thereof.
- As used herein, the term “metabolite” refers to a compound generated in vivo after a drug is applied to a subject in need thereof.
- As used herein, the term “pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the parent compound, and can be prepared in the following manner: a proton-accepting moiety is partially protonated and/or a proton-donating moiety is partially deprotonated. It should be noted that the partial protonation of the proton-accepting moiety results in a cationic species, the charge of which is balanced by the presence of a physiological anion, while the partial deprotonation of the proton-donating moiety results in an anionic species, the charge of which is balanced by the presence of a physiological cation.
- A pharmaceutically acceptable salt of the compound of Formula (I) includes an acid addition salt and a base addition salt thereof.
- A suitable acid addition salt is formed from an acid which forms a non-toxic salt and includes an inorganic acid and an organic acid. In the present invention, a suitable inorganic acid is an acid as defined in the field of chemistry, such as hydrochloric acid, sulfuric acid or phosphoric acid, etc. A suitable organic acid includes an organic sulfonic acid, an organic carboxylic acid, or an amino acid, etc. A suitable organic sulfonic acid is e.g. C6-16 aryl sulfonic acid, C6-16 heteroaryl sulfonic acid, or C1-16 alkyl sulfonic acid, and a suitable organic carboxylic acid is e.g. monocarboxylic acid or polycarboxylic acid, including C1-16 alkyl carboxylic acid, C6-16 aryl carboxylic acid and C4-16 heteroaryl carboxylic acid. The organic carboxylic acid can also be e.g. an amino acid, various kinds of which are suitable, particularly natural amino acids which are found as components of proteins. Specific examples of salts formed from the above acids include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts.
- A suitable base addition salt is formed from a base which forms non-toxic salts and includes an inorganic base and an organic base. Specific examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
- For a review on suitable salts, see “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of compounds of the present invention are known to a person skilled in the art.
- As used herein, the term “isomer” refers to a different compound with a same molecular formula, and includes a stereoisomer. The term “stereoisomer” is an isomer that merely differs in the arrangement of atoms in space. α- and β-indicate the specific stereochemical configuration of a substituent at an asymmetric carbon atom in a chemical structure as drawn.
- The compound of the present invention may have one or more chiral centers, and may, therefore, exist in a variety of stereoisomeric configurations. Due to the presence of these chiral centers, the compound of the present invention can exist as a racemate, a mixture of enantiomers, as well as mixtures of each enantiomer and a diastereomer and of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of “the compound of the present invention”. The terms “R” and “S” are used in organic chemistry to denote specific configurations of a chiral center.
- The compound of the present invention can exist as a hydrate, or as a solvate, wherein the compound of the present invention contains a polar solvent, in particular water, methanol or ethanol for example as a structural element of the crystal lattice of the compound. The amount of the polar solvent, in particular water, may exist in a stoichiometric or non-stoichiometric ratio.
- The present invention includes all possible crystalline forms, or polymorphs, of the compound of the present invention, either as a single polymorph, or as a mixture of more than one polymorphs, in any ratio.
- The term “optional” or “optionally” means an element may be, but is not necessarily, present in a corresponding situation or condition. The term comprises an example wherein a substituent is or is not present, and also comprises an example which is substituted with one or more substituents. The term “substituted” means that one or more (e.g., one, two, three, or four) hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. In the compound of Formula (I) of the present invention, the expression “optionally substituted” covers situations where a compound is substituted with one or more substituents, and when the expression “optionally substituted” refers to a situation where a compound is substituted with multiple substituents, the substituents may be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from oxygen (O), nitrogen (N), and sulfur (S), and such saturated, unsaturated or aromatic ring may further form a ring with the group being substituted. For example, specific examples of the term “optionally substituted aryl” include dihydrobenzothiophenyl, as well as a group having the follow structure:
- As used herein, the term “alkyl” refers to an unbranched or branched, chain or cyclic, saturated, monovalent hydrocarbon residue, which preferably contains 1 to 14 carbon atoms (C1-14 alkyl), more preferably contains 1 to 10 carbon atoms (C1-10 alkyl), more preferably contains 1 to 6 carbon atoms (C1-6 alkyl), and particularly preferably contains 1 to 4 carbon atoms (C1-4 alkyl). Examples of an alkyl group include, but are not limited to, lower alkyl groups including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl (e.g., hept-4-yl) and octyl.
- As used herein, the term “cycloalkyl” refers to a saturated, non-aromatic, monocyclic or polycyclic (such as bicyclic) hydrocarbon ring. When a cycloalkyl comprises two or more rings, the rings can be fused together. In its ring, a cycloalkyl group may contain 3 to 10 atoms (C3-10 cycloalkyl), preferably 3 to 8 ring atoms (C3-8 cycloalkyl), more preferably 3 to 6 ring atoms (C3-6 cycloalkyl), and particularly preferably 3 to 4 ring atoms (C3-4 cycloalkyl). The cycloalkyl group includes, but is not limited to monocycles such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicycicles, including spiro, fused, or bridged systems (such as bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl or bicyclo[5.2.0]nonanyl, decahydronaphthalenyl, etc.), optionally substituted with 1 or more (such as 1 to 3) suitable substituents.
- Unless otherwise indicated, the term “alkenyl” as used herein refers to a hydrocarbon residue having 2 to 10 carbon atoms and having one or two olefinic double bonds, and it preferably contains 2-8 carbon atoms (C2-8 alkenyl), more preferably contains 2 to 6 carbon atoms (C2-6 alkenyl), and particularly preferably contains 2 to 4 carbon atoms (C2-4 alkenyl). Examples of an alkenyl group include vinyl, 1-propenyl, 2-propenyl or 2-butenyl, etc.
- Unless otherwise indicated, the term “alkynyl” as used herein refers to an unbranched or branched hydrocarbon chain group having 2 to 10 carbon atoms (C2-10 alkynyl), and having one or two triple bonds, and it preferably contains 2-8 carbon atoms (C2-8 alkynyl), more preferably contains 2 to 6 carbon atoms (C2-6 alkynyl), and particularly preferably contains 2 to 4 carbon atoms (C2-4 alkynyl). Examples of an alkynyl group are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.
- As used herein, the term “amino” represents —NH2, and alkylamino represents —NR′R″, wherein R and R″ are the same or different, and are H or an alkyl or cycloalkyl group as defined above.
- As used herein, the term “alkoxy” represents —O-alkyl, wherein alkyl is as defined above (e.g., C1-14 alkyl, C1-10 alkyl, C1-6 alkyl, or C1-4 alkyl), such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy, etc., as well as isomers thereof.
- As used herein, the term “halogen” or “halo” refers to fluorine, chlorine, bromine or iodine.
- As used herein, the term “haloalkyl” refers to the alkyl group as defined above, wherein 1, 2, 3, or more hydrogen atoms are replaced with halogens. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl.
- As used herein, the term “haloalkoxy” refers to the alkoxy group as defined above, wherein 1, 2, 3, or more hydrogen atoms are replaced with halogens.
- As used herein, the term “acyl” represents a group of formula —C(═O)R, wherein R is hydrogen or an alkyl group as defined above (e.g., C1-14 alkyl, C1-10 alkyl, C1-6 alkyl, or C1-4 alkyl).
- As used herein, the term “alkylcarbonyl” represents a group of formula —C(═O)R, wherein R is an alkyl group as defined above (e.g., C1-14 alkyl, C1-10 alkyl, C1-6 alkyl, or C1-4 alkyl).
- As used herein, the term “amido” represents a group of formula —NC(═O)R′R″, wherein R and R′ are the same or different, and are hydrogen or an alkyl group as defined above (e.g., C1-14 alkyl, C1-10 alkyl, C1-6 alkyl, or C1-4 alkyl).
- As used herein, the term “hydroxyalkyl” represents a group of formula —R—OH, wherein R is an alkylene group. Unless otherwise indicated, the term “alkylene” as used herein refers to a divalent, saturated, straight hydrocarbon group containing 1 to 10 carbon atoms (C1-10 alkylene), more preferably 1 to 6 carbon atoms (C1-6 alkylene), and particularly preferably 1 to 4 carbon atoms (C1-4 alkylene), or a branched, saturated, divalent hydrocarbon group containing 3-10 carbon atoms (C3-10 alkylene), more preferably 3-8 carbon atoms (C3-8 alkylene), and particularly preferably 3-5 carbon atoms (C3-5 alkylene). Examples of an alkylene group include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, butylene and 2-ethylbutylene, etc.
- As used herein, the term “aryl” refers to a group having at least one aromatic ring, i.e., having a conjugated i-electron system, and includes a monocyclic aryl group, and a bicyclic aryl group. It contains 6-14 carbon atoms (C6-14 aryl), such as phenyl and naphthyl, etc. Optionally substituted aryl includes an aryl group substituted with multiple substituents, and the substituents can be appropriately connected to each other to form a saturated, unsaturated or aromatic ring containing 0-3 heteroatoms selected from N, O, and S. The aryl group preferably includes the following groups:
- As used herein, the term “aralkyl” represents group R′R″—, wherein R′ is an aryl group as defined herein, and R″ is an alkylene group as defined herein. It is to be understood that the point of attachment of the aralkyl moiety would be at the alkylene group. Normally, the aryl group may contain 6-14 carbon atoms, and the alkyl group may contain 1-6 carbon atoms. Exemplary aralkyl includes, but is not limited to benzyl, 4-fulorobenzyl, phenylethyl, phenylpropyl, and phenylbutyl.
- As used herein, the term “aryloxy” represents —O—R, and R is an aryl group as defined above.
- As used herein, the term “arylcarbonyl” represents a group of formula —C(═O)Ar, wherein Ar is an aryl group as defined above.
- As used herein, the term “heterocyclyl” refers to a 3-16 membered saturated or unsaturated ring containing 1-4 (e.g., one, two, three, or four) heteroatoms selected from N, O, S, and P, with the remaining atoms as carbon atoms. In particular, a 3-10 membered heterocyclyl is a group having 3-10 carbon atoms as well as heteroatoms in its rings, such as, but not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, pyrrolidinonyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl.
- As used herein, the term “heteroaryl” refers to a cyclic aromatic group having 1 to 3 heteroatoms selected from N, O and S atoms as ring atoms, with the remaining ring atoms as carbon atoms, wherein the ring is a 4-16 membered monocycle or fused ring, preferably a 5-12 membered monocycle or fused ring, or a 5-8 membered monocycle or fused ring. Examples of a heteroaryl group include, but are not limited to, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrrolyl, pyrazolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, pyridazinyl, phthalazinyl, phthalazin-1-(2H)-1-yl, pyrido[3,2-d]pyridazin-5(6H)-8-yl, triazinyl, etc., as well as benzo derivatives thereof.
- As used herein, the term “heteroarylcarbonyl” is defined similar to the definition of “arylcarbonyl group”, and represents a group of formula —C(═O)R, wherein R is a heteroaryl group as defined above.
- As used herein, the term “heteroaryloxy” represents a group of formula heteroaryl-O—, wherein the heteroaryl group is as defined above.
- As used herein, the term “sulfonamido” represents a group of formula —SO2NR′R″, wherein R and R′ are the same or different, and are each independently hydrogen or an alkyl or cycloalkyl group as defined above.
- As used herein, the term “carboxyl” represents a group of formula —COOH, and the term “carboxylate” represents —COOR, wherein R each independently represents an alkyl group as defined above.
- In the general formula or specific compounds of the present invention, a group, or an atom, or a radical each includes a group, or an atom, or a radical with substitution of an isotope, for example, “hydrogen” includes H, 2H (deuterium), or 3H (tritium); a C1-14 alkyl group includes an alkyl group wherein one or more, or all of the carbon atoms are 12C, 13C, or 14C; and further exemplary examples include isotopes of N, P, or O.
- As used herein, the term “pharmaceutically acceptable carrier” refers to inactive ingredients in a pharmaceutical composition or a pharmaceutical preparation that do not cause significant irritation and do not interfere with the nature of the biologically active compounds applied in an organism, and it includes a diluent, adjuvant, excipient or equivalent pharmaceutically acceptable medium administered together with a therapeutic agent.
- As used herein, the term “excipient” refers to a substance for the preparation of a pharmaceutical composition, and it is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes various excipients suitable for veterinary use as well as human pharmaceutical use.
- The pharmaceutically acceptable carrier which can be employed in the pharmaceutical composition of the present invention includes, but is not limited to sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. Physiological salines as well as aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in e.g. Remington's Pharmaceutical Sciences (1990).
- As used herein, the term “formulation” or “dosage form” shall include solid, semi-solid, liquid, or gas formulations. The formulation or dosage form includes, but is not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, salves, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Those skilled in the art will appreciate that, depending on the desired dose and pharmacokinetic parameters, the compound of the present invention may be prepared as different formulations.
- The unit dosage range of the compound of the present invention is 0.1-1000 mg, preferred unit dosage range is 1-800 mg, more preferred unit dosage range is 10-600 mg, particularly preferred unit dosage range is 50-450 mg, and the most preferred unit dosage range is 100-300 mg. The formulation or dosage form of the present invention may contain a single or multiple unit dosage of the compound of the present invention.
- The compound of the present invention is preferably for oral administration. In various situations, other administration routes may be employed or even preferred, such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, or transdermal administration, or administration via buccal, nasal, transmucosal, topical, route, as an ophthalmic formulation, or via inhalation. Transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. The compound of the present invention may also be administered by the percutaneous, intramuscular, intranasal or intrarectal route in particular circumstances. The route of administration may be varied in any way, depending on the physical properties of the drugs, the convenience of the patient and the caregiver, and other relevant conditions (Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).
- In another aspect, the present invention provides use of the compound of the present invention for simultaneous, separate or sequential administration in combination with an additional therapeutic agent (such as an additional anti-cancer/anti-tumor agent, or an additional anti-viral agent).
- The dosage range of the compound of the present invention or a product comprising the same (such as a pharmaceutical composition, a pharmaceutical formulation, or a dosage form) is 0.1-1000 mg/kg body weight per day, preferred dosage range is 1-800 mg/kg body weight per day, preferred dosage range is 10-600 mg/kg body weight per day, particularly preferred dosage range is 100-400 mg/kg body weight per day, and most preferred dosage range is 120-250 mg/kg body weight per day. The exact dosage required for treating a patient may be determined by a physician in view of the stage and severity of the disease as well as patient's specific need and response.
- Unless otherwise indicated, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- As used herein, the term “mammal” includes a human or non-human animal. An exemplary human subject includes a human subject having a disease or disorder (such as one described herein) (referred to as a patient), or a normal subject. The term “non-human animal” as used herein includes non-human primates, livestock and/or domesticated animals, such as sheep, dog, cat, cow, pig and the like.
- The present invention is further described in detail with reference to the following examples and specific embodiments. However, it should not be construed that the scope of the present invention is merely limited to the following examples, technical solutions achieved based on the contents of the present invention are all within the scope of the present invention.
- The abbreviations as used herein have the following meanings:
-
Abbreviation Meaning AcOH acetic acid AcOK potassium acetate Ac2O acetic anhydride aq. aqueous solution BCl3 boron trichloride BnBr benzyl bromide BzCl benzoyl chloride Bz2O benzoic anhydride m-CPBA metachloroperbenzoic acid DAST diethylaminosulfurtrifluoride DCE dichloroethane DCM dichloromethane DMAP 4-dimethylaminopyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide Et3N triethylamine HBr hydrogen bromide HCl hydrochloric acid H2O water HPLC high-performance liquid chromatography H2SO4 sulphuric acid KF potassium fluoride MeOH methanol MsCl methylsulfonyl chloride NaBH4 sodium borohydride NaH sodium hydride Na2S sodium sulfide NH3 amonia NaIO4 sodium periodate NaOMe sodium methoxide SO2Cl2 sulfonyl chloride TBAF tetrabutylammonium fluoride TBDPSCl tert-butyldiphenylchlorosilane TFA trifluoroacetic acid THF tetrahydrofuran TMSOTf trimethylsilyl triflate -
- (a) SO2Cl2, imidazole, DCM; (b) KF, 2-methoxylethanol, reflux; (c) 2M HCl, THF; (d) BzCl, pyridine, DCM; (e) MsCl, pyridine; (f) NaOMe, MeOH; (g) thiourea, MeOH, reflux; (h) AcOK, Ac2O, AcOH, reflux; (i) 90% TFA; (j) NaIO4, MeOH, H2O; (k) HCl, MeOH, reflux; (1) BzCl, pyridine; (m) H2SO4, Ac2O, AcOH; (n) HBr, AcOH, DCM; (o) silylated N-acetylcytosine, 80° C.; (p) aq. NH3, MeOH, HPLC separation.
- 1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)cytosine (Compound A) employed in the present example was prepared by a method in a literature (J. Org. Chem. 1999, 64, 7912-7920).
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to −60° C. A solution of phenol (940 mg, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine ethyl ester hydrochloride (1.53 g, 10 mmol) was added. After the reaction solution was cooled to −60° C., a solution of triethylamine (2.02 g, 20 mmol) in dichloromethane (5 mL) was dropwise added, and the reaction solution was allowed to warm to room temperature. A solution of pentafluorophenol (1.84 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was dropwise added to the above solution, which was then stirred at −5° C. for 2 h. After completion of the reaction, the reaction solution was quenched by addition of water, extracted with ethyl acetate, dried, concentrated and purified by column chromatography, to give the title compound (Compound B1).
- Compound A (260 mg, 1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), and air is replaced with argon for three times. Tert-Butylmagnesium chloride (1.0 mol/L, 1.2 mL, 1.2 mmol) was dropwise added at −10° C. The reaction mixture was stirred for 2 h, and reacted for 0.5 h after being warmed to room temperature. A solution of an intermediate, compound B1, (0.53 g, 1.2 mmol), in anhydrous THF (10 mL) was dropwise added. The reaction was conducted at 30° C. for 15 h, then quenched by dropwise addition of methanol (10 mL), concentrated and purified by column chromatography, to give compound C1.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 517.7 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 5H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 3H), 3.80-3.78 (m, 1H), 1.28-1.23 (m, 6H).
- Compound C2 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine benzyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 579.6 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 10H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.36 (s, 2H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
- Compound C3 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine phenyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 565.1 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 10H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to −60° C. A solution of 4-fluorophenol (1.12 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine isopropyl ester hydrochloride (1.53 g, 10 mmol) was added. After the reaction solution was cooled to −60° C., a solution of triethylamine (2.02 g, 20 mmol) in dichloromethane (5 mL) was dropwise added, and the reaction solution was allowed to warm to room temperature. A solution of pentafluorophenol (1.84 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was dropwise added to the above solution, which was then stirred at −5° C. for 2 h. After completion of the reaction, the reaction solution was quenched by addition of water, extracted with ethyl acetate, dried, concentrated and purified by column chromatography, to give the title compound.
- Compound A (260 mg, 1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), and air is replaced with argon for three times. Tert-Butylmagnesium chloride (1.0 mol/L, 1.2 mL, 1.2 mmol) was dropwise added at −10° C. The reaction mixture was stirred for 2 h, and reacted for 0.5 h after being warmed to room temperature. A solution of (S)-isopropyl 2-(((pentafluorophenoxy)(4-fluorophenoxy)phosphoryl)amino)propanoate (566 mg, 1.2 mmol) in anhydrous THF (10 mL) was dropwise added. The reaction was conducted at 30° C. for 15 h, then quenched by dropwise addition of methanol (10 mL), concentrated and purified by column chromatography, to give compound C4.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 549.3 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) (δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.35-7.17 (m, 4H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
- Compound C5 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-chlorophenol, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 565.4 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) (δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.30-7.17 (m, 4H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
- Compound C6 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-bromophenol, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 611.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.28-7.17 (m, 4H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H).
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to −60° C. A solution of phenol (1.12 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and 2-methyl-alanine isopropyl ester hydrochloride (1.82 g, 10 mmol) was added. After the reaction solution was cooled to −60° C., a solution of triethylamine (2.02 g, 20 mmol) in dichloromethane (5 mL) was dropwise added, and the reaction solution was allowed to warm to room temperature. A solution of pentafluorophenol (1.84 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was dropwise added to the above solution, which was then stirred at −5° C. for 2 h. After completion of the reaction, the reaction solution was quenched by addition of water, extracted with ethyl acetate, dried, concentrated and purified by column chromatography, to give the title compound.
- Compound A (260 mg, 1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), and air is replaced with argon for three times. Tert-Butylmagnesium chloride (1.0 mol/L, 1.2 mL, 1.2 mmol) was dropwise added at −10° C. The reaction mixture was stirred for 2 h, and reacted for 0.5 h after being warmed to room temperature. A solution of isopropyl 2-methyl-2-(((pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate (582 mg, 1.2 mmol) in anhydrous THF (10 mL) was dropwise added. The reaction was conducted at 30° C. for 15 h, then quenched by dropwise addition of methanol (10 mL), concentrated and purified by column chromatography, to give compound C7.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 545.5 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 5H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 1.27 (s, 6H), 1.17 (d, J=5.2 Hz, 6H).
- (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate employed in the present invention was prepared by a method in a literature (J. Org. Chem. 2011, 76, 8311-8319).
- Compound C8 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 531.1 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 5H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.17 (d, J=5.2 Hz, 6H).
- 1-((2R,3 S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-5-fluorocytosine employed in the present invention was prepared by a method in a literature (Bioorg. Med. Chem. 2000, 8, 1545-1558).
- Compound C9 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and 1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-5-fluorocytosine as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 549.5 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 8.23 (d, J=7.3 Hz, 1H), 7.38-7.31 (m, 3H), 7.23-7.16 (m, 5H), 6.52 (dd, J=4 Hz, 14 Hz, 1H), 6.05-6.03 (m, 2H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.25 (d, J=6.4 Hz, 3H), 1.14 (d, J=5.2 Hz, 6H).
- (2R,3S,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ol employed in the present invention was prepared by a method in a literature (Bioorg. Med. Chem. 2000, 8, 1545-1558).
- Compound C10 was prepared according to a method similar to that of Example 1, using (S)-isopropyl 2-(((S)-(pentafluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, and (2R,3S,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrothiophen-3-ol as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 589.4 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 8.42 (s, 1H), 7.32-7.15 (m, 8H), 6.50 (dd, J=4 Hz, 14 Hz, 1H), 6.07-6.03 (m, 2H), 5.72 (d, J=7.6 Hz, 1H), 5.01-4.87 (m, 2H), 4.37-4.32 (m, 2H), 4.15-4.12 (m, 1H), 3.80-3.78 (m, 1H), 1.24 (d, J=6.4 Hz, 3H), 1.15 (d, J=5.2 Hz, 6H).
- Compound C8 (53 mg, 0.1 mmol) and ethyldiisopropylamine (26 mg, 0.2 mmol) was dissolved in dry dichloromethane (2 mL). 2-propylpentanoyl chloride (17 mg, 0.1 mmol) was added at 0° C. The reaction mixture was warmed to room temperature, and stirred overnight. The reaction mixture was quenched by addition of saturated NaHCO3, extracted with ethyl acetate, dried, concentrated, and purified by column chromatography, to give compound C11.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 657.7 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=3.4 Hz, 1H), 7.38 (t, J=7.6 Hz, 2H), 7.31-7.17 (m, 5H), 6.56 (dd, J=4 Hz, 14 Hz, 1H), 6.09-6.03 (m, 2H), 5.77 (d, J=7.6 Hz, 1H), 5.03-4.87 (m, 2H), 4.36-4.32 (m, 2H), 4.14-4.12 (m, 1H), 3.80-3.78 (m, 1H), 2.50-2.47 (m, 1H), 1.43-1.22 (m, 17H), 0.94-0.91 (m, 6H).
-
- (a) BnBr, NaH, DMF, THF; (b) 2M HCl, THF; (c) NaIO4, H2O, MeOH; (d) NaBH4, MeOH; (e) 5% HCl/MeOH; (f) MsCl, pyridine; (g) Na2S, DMF, 100° C.; (h) 4M HCl, THF; (i) NaBH4, MeOH; (j) TBDPSCl, imidazole, DMF; (k) Ac2O, DMSO; (1) DAST, DCM; (m) BCl3, DCM, −78° C.; (n) Bz2O, Et3N, DMAP, CH3CN; (o) m-CPBA, DCM, −78° C.; (p) silylated N-acetylcytosine, TMSOTf, DCE, 0° C.; (q) TBAF, THF; (r) aq. NH3, MeOH, HPLC separation.
- 1-((2R,4S,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)cytosine employed in the present invention was prepared by a method in a literature (J. Org. Chem. 1997, 62, 3140-3152).
-
- The data for structural characterization of the compound are as follows.
- ESI-MS: 549.5 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.96 (d, J=3.4 Hz, 1H), 7.35 (m, 3H), 7.23-7.17 (m, 5H), 6.46 (dd, J=4 Hz, 14 Hz, 1H), 5.98-5.95 (m, 2H), 5.84 (d, J=7.6 Hz, 1H), 5.35 (brs, 1H), 4.36-4.32 (m, 2H), 4.17-4.14 (m, 1H), 3.85-3.80 (m, 1H), 1.13 (d, J=6.4 Hz, 3H), 1.09 (d, J=5.2 Hz, 6H).
- Phosphorus oxychloride (1.53 g, 10 mmol) was dissolved in dichloromethane (10 mL), and was then cooled to −60° C. A solution of sesamol (1.38 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was slowly dropwise added. After stirred overnight at room temperature, the reaction solution was cooled to 0° C., and L-alanine isopropyl ester hydrochloride (1.53 g, 10 mmol) was added. After the reaction solution was cooled to −60° C., a solution of triethylamine (2.02 g, 20 mmol) in dichloromethane (5 mL) was dropwise added, and the reaction solution was allowed to warm to room temperature. A solution of pentafluorophenol (1.84 g, 10 mmol) and triethylamine (1.01 g, 10 mmol) in dichloromethane (10 mL) was dropwise added to the above solution, which was then stirred at −5° C. for 2 h. After completion of the reaction, the reaction solution was quenched by addition of water, extracted with ethyl acetate, dried, concentrated and purified by column chromatography, to give the title compound.
- Compound A (260 mg, 1 mmol) was dissolved in anhydrous tetrahydrofuran (50 mL), and air is replaced with argon for three times. Tert-Butylmagnesium chloride (1.0 mol/L, 1.2 mL, 1.2 mmol) was dropwise added at −10° C. The reaction mixture was stirred for 2 h, and reacted for 0.5 h after being warmed to room temperature. A solution of (S)-isopropyl 2-(((pentafluorophenoxy)(benzo[d][1,3]dioxol-5-yloxy)phosphoryl)amino)propanoate (596 mg, 1.2 mmol) in anhydrous THF (10 mL) was dropwise added. The reaction was conducted at 30° C. for 15 h, then quenched by dropwise addition of methanol (10 mL), concentrated and purified by column chromatography, to give the title compound.
-
- The mixture of the diastereomers obtained in the previous step was separated by preparative HPLC using the following separation conditions: octadecyl bonded silica gel was used as filler (20×250 mm, 5 μm), column temperature was 40° C., flow rate was 10.0 mL/min, detection wavelength was 220 nm, mobile phase A was water (neutral), mobile phase B was methanol, and linear gradient elution was performed. The first main peak was collected, and freeze-dried to obtain (S)-isopropyl 2-(((R)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(benzo[d][1,3]dioxol-5-yloxy)phosphoryl)amino)propanoate (C13), 17 mg; and the second main peak was collected, and freeze-dried to obtain (S)-isopropyl 2-(((S)-(((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)(benzo[d][1,3]dioxol-5-yloxy)phosphoryl)amino)propanoate (C14), 30 mg.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 575.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.93 (d, J=8 Hz, 1H), 7.75 (bs, 1H), 7.46 (bs, 1H), 6.88-6.83 (m, 2H), 6.67-6.65 (m, 1H), 6.51 (d, J=8 Hz, 1H), 5.76 (d, J=7.6 Hz, 1H), 4.90-4.86 (m, 4H), 4.31 (bs, 2H), 4.13-4.11 (m, 1H), 3.78-3.76 (m, 1H), 3.50 (bs, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.59.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 575.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) (δ 7.93 (d, J=8 Hz, 1H), 7.75 (bs, 1H), 7.46 (bs, 1H), 6.88-6.83 (m, 2H), 6.67-6.65 (m, 1H), 6.51 (d, J=8 Hz, 1H), 5.76 (d, J=7.6 Hz, 1H), 4.90-4.86 (m, 4H), 4.31 (bs, 2H), 4.13-4.11 (m, 1H), 3.78-3.76 (m, 1H), 3.50 (bs, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H). 31P NMR (DMSO-d6, 162 MHz) (δ 4.50.
-
- Compound C15 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, phenol, L-alanine 4-fluorobenzyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 597.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.86 (d, J=8 Hz, 1H), 7.67-7.17 m, 12H), 6.54 (dd, J=4 Hz, 14 Hz, 1H), 6.21-6.15 (m, 1H), 6.07 (bs, 1H), 5.78 (d, J=4 Hz, 1H), 5.11 (bs, 2H), 4.31 (bs, 2H), 4.12-4.10 (m, 1H), 3.94-3.92 (m, 1H), 3.47 (bs, 1H), 1.26 (d, J=8 Hz, 3H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.02.
-
- Compound C16 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 5-hydroxy-2,3-dihydrobenzo[1,4]dioxine, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 589.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) (δ 7.93 (d, J=8 Hz, 1H), 7.34 (bs, 1H), 7.26 (bs, 1H), 6.91-6.89 (m, 1H), 6.81-6.73 (m, 1H), 6.61-6.56 (m, 1H), 6.11-6.07 (m, 1H), 6.01-5.85 (m, 1H), 5.80-5.75 (m, 1H), 5.04-4.82 (m, 1H), 4.37-4.17 (m, 7H), 3.87-3.83 (m, 1H), 3.50 (bs, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.58.
-
- Compound C17 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 4-hydroxy-7-fluoro-2,3-dihydrobenzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 591.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) (δ 7.89 (d, J=8 Hz, 1H), 7.37 (bs, 1H), 7.29 (bs, 1H), 7.10-7.06 (m, 1H), 6.76-6.73 (m, 1H), 6.60-6.54 (m, 1H), 6.15-6.10 (m, 2H), 5.81-5.78 (m, 1H), 5.10-4.90 (m, 2H), 4.72-4.61 (m, 3H), 4.36-4.34 (m, 2H), 4.25-4.20 (m, 1H), 3.78-3.75 (m, 1H), 3.53-3.50 (m, 3H), 3.38-3.35 (m, 2H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.65.
- (S)-isopropyl 2-(((((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)methoxy)((2,3-dihydrobenzofuran-6-yl)oxy)phosphoryl)amino)propanoate (C18)
- Compound C18 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 6-hydroxy-2,3-dihydrobenzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 573.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.89 (d, J=8 Hz, 1H), 7.35 (bs, 1H), 7.26 (bs, 1H), 7.20-7.18 (m, 1H), 6.68-6.66 (m, 2H), 6.59-6.56 (m, 1H), 6.08-6.03 (m, 1H), 5.80-5.79 (m, 1H), 5.02-4.88 (m, 2H), 4.57 (t, J=8 Hz, 3H), 4.60-4.55 (m, 2H), 4.36-4.32 (m, 1H), 3.80-3.75 (m, 1H), 3.47 (bs, 1H), 3.17-3.13 (m, 2H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.20.
-
- Compound C19 was prepared according to a method similar to that of Example 1, using phosphorus oxychloride, 6-hydroxy-benzofuran, L-alanine isopropyl ester hydrochloride, pentafluorophenol, and Compound A as starting materials.
- The data for structural characterization of the compound are as follows.
- ESI-MS: 571.2 (M+1)
- 1H NMR (DMSO-d6, 400 MHz) δ 7.89 (d, J=8 Hz, 1H), 7.54 (s, 1H), 7.35 (bs, 1H), 7.26 (bs, 1H), 7.20-7.18 (m, 1H), 6.68-6.66 (m, 3H), 6.59-6.56 (m, 1H), 6.08-6.03 (m, 1H), 5.80-5.79 (m, 1H), 5.02-4.88 (m, 2H), 4.60-4.55 (m, 3H), 4.36-4.32 (m, 1H), 3.80-3.75 (m, 1H), 3.47 (bs, 1H), 1.23 (d, J=6.4 Hz, 3H), 1.16 (d, J=5.2 Hz, 6H).
- 31P NMR (DMSO-d6, 162 MHz) δ 4.35.
- Biological Assays
- This experimental example was used for the evaluation of the effectiveness of the compounds of the present invention in inhibiting the proliferation of human gastric cancer NCI-N87, colorectal cancer HCT-116, colorectal cancer HCT-15, and pancreatic cancer BxPC-3 cell lines.
- 1. Cells for the Experiment
- The tumor cell lines employed in the present experiment were gastric cancer cell NCI-N87 (obtained from Guangzhou Jennio Biological Technology Co., Ltd.), colorectal cancer cell HCT-116 (obtained from Chengdu Center for Safety Evaluation of Drugs), colorectal cancer cell HCT-15 and pancreatic cancer cell BxPC-3 (both obtained from ATCC, US).
- The above cell lines were cultured as a monolayer in vitro, and the culture conditions were as follows. Each of the cell lines is cultured in a corresponding culture medium (RPMI-1640, IMDM and L-15 culture medium (manufacturer: Gibco)) supplemented with 10% heat inactivated Fetal Bovine Serum (manufacturer: Sigma), in an incubator at 37° C. and 5% CO2. The cells were subcultured by treatment with trypsin-EDTA digestion.
- 2. Sample Preparation
- For each type of tumor cells, a blank group, a vehicle group (containing 1‰ DMSO) and 8 groups with a test compound at concentrations of 5 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1000 nM, 5000 nM, and 10000 nM (with each concentration in triplicate) were set.
- Appropriate amounts of test compounds were weighted, and dissolved in DMSO (cell culture grade, Sigma) to prepare stock solutions of various concentration gradients according to desired concentrations. During incubation, they were diluted by 1000 times as necessary, and incubation solutions with various drug concentrations were prepared (compound stock solution: medium containing 2% FBS=1:1000).
- 3. Experimental Method
- The experiment was performed according to a CCK-8 method as described below. Cancer cells to be tested were seeded in a 96-well culture plate at a concentration of 5˜10×104/mL (100 μL/well), followed by incubation at 37° C. and 5% CO2 for 24 h. The medium was discarded, and incubation solutions with different drug concentrations (200 μL) were respectively added to each well, and the cells were further incubated for 72 h. After the incubation, a CCK-8 solution (20 μL/well) was added to each well to be tested, and the incubation was continued for 4 h in the incubator. OD values at two wavelengths (Detection wavelength: 450 nm, and reference wavelength: 650 nm) were determined on a multifunctional fully-automatic microplate reader.
- The inhibitory rate of tumor cell growth was calculated according to the following formula:
-
Inhibitory rate=[(ODvehicle−ODblank)−(ODdrug−ODblank)]/(ODvehicle−ODblank)*100% - Based on the inhibitory rate, a concentration-inhibitory rate curve was fit using GraphPad prism 5.0 software, and IC50 was calculated.
-
FIG. 1 shows that the compound of Example 8 (C8) has potent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-116, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3 at the above 8 concentrations. IC50 values of example compounds of the present invention for each type of cancer cells are shown in table 1-1 to 1-4. -
TABLE 1-1 IC50 (μM) Compound gastric cancer cell NCI-N87 C2 0.25 C8 0.483 C13 0.55 C14 0.18 C15 0.24 C16 0.30 C17 0.63 C19 0.35 -
TABLE 1-2 IC50 (μM) Compound colorectal cancer cell HCT-116 C8 0.485 -
TABLE 1-3 IC50 (μM) Compound colorectal cancer cell HCT-15 C2 2.97 C8 1.964 C14 9.78 C15 4.08 -
TABLE 1-4 IC50 (μM) Compound pancreatic cancer cell BxPC-3 C2 1.28 C8 0.705 C14 2.82 C15 1.80 C16 1.15 C17 3.80 C18 2.74 C19 0.68 - According to the experimental results, the IC50 values of the compounds of the present invention were in the range of 0.1-1 μM for gastric cancer cell NCI-N87, in the range of 0.1-1 μM for colorectal cancer cell HCT-116, in the range of 0.5-10 μM for colorectal cancer cell line HCT-15, and in the range of 0.1-5 μM for pancreatic cancer cell BxPC-3. As such, the compounds of the present invention have inhibitory activity on tumor cells.
- The compound of Example 8 (C8) of the present invention has a potent anti-tumor effect in vitro, and has excellent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-116, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3. The compounds of Examples 2, 14 and 15 each have excellent inhibitory effects on gastric cancer cell NCI-N87, colorectal cancer cell HCT-15, and pancreatic cancer cell BxPC-3. The compounds of Examples 16, 17 and 19 have excellent inhibitory effects on gastric cancer cell NCI-N87 and pancreatic cancer cell BxPC-3. The compound of Example 13 has an excellent inhibitory effect on gastric cancer cell NCI-N87, and the compound of Example 18 has an excellent inhibitory effect on pancreatic cancer cell BxPC-3.
- This experimental example was used for the evaluation of the effectiveness of the compounds of the present invention in inhibiting the proliferation of a subcutaneous xenograft of human tumor cells via various routes of administration.
- As an example, the present experimental example investigated variations in tumor volume and body weight of mice with subcutaneous xenografts of human colorectal cancer cell line HCT-116 and gastric cancer cell line NCI-N87 after compound C8 was administered via various routes, so as to determine the pharmacological efficacy and toxicity of each test sample on mice bearing a tumor of colorectal cancer cell HCT-116 or gastric cancer cell NCI-N87.
- 1. Cell Lines for the Test
- Gastric cancer cell NCI-N87 and colorectal cancer cell HCT-116 were cultured as a monolayer in vitro, and the culture conditions were RPMI-1640 culture medium supplemented with 10% heat inactivated Fetal Bovine Serum, and incubation in an incubator at 37° C. and 5% CO2. The cells were subcultured by treatment with trypsin-EDTA digestion.
- 2. Tumor Cell Inoculation and Grouping of Animals
- The tumor cells were respectively inoculated into BALB/c nude mice (SPF grade, female, 16-18 g per mouse, about 6 to 8 weeks old, Beijing Vital River Laboratory Animal Technology Co., Ltd.).
- Each nude mouse was inoculated with about 2.5×106 HCT-116 tumor cells or about 3×106 NCI-N87 tumor cells (suspended in 0.1 ml PBS) subcutaneously into the underarm of the right flank. After the inoculated tumor reached a size in the range of about 100-200 mm3, nude mice bearing a tumor that is too small (smaller than 100 mm3) or too big (bigger than 200 mm3) were removed from the study, and the remaining ones were randomized into groups.
- 3. Sample Preparation
- Sulfobutyl ether-β-cyclodextrin (SE-β-CD) was formulated with physiological saline to form a 10% solution, which was then filtered through a 0.22 μm sterile filter for later use.
- An appropriate amount of the test compound was weighted, and added in DMSO. The resultant solution was vortexed to uniformity, and the 10% solution of SE-β-CD was added according to the desired concentration. The solution was vortexed to uniformity, and the final concentration of DMSO was adjusted to 5%. A gemcitabine injection (a positive control) was directly diluted to the desired concentration with physiological saline. A 10% solution of SE-β-CD containing 5% DMSO was prepared as a vehicle control.
- 4. Test Method
- Mice bearing a tumor having a volume of about 100-200 mm3 were selected, and randomized into 5 groups (8 mice per group). The dosing volume was 10 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed twice a week for 3 weeks. The tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- 5. Test Indexes
- 5.1 Tumor Volume
- The diameter of a tumor was measured, and the tumor volume was calculated according to the following formula: V=0.5a×b2, wherein a and b respectively represent the major and minor diameters of a tumor. The anti-tumor effect was evaluated by the tumor growth inhibition (TGI) (%).
-
TGI (%)=[1−(V T-end −V T-start)/(V C-end −V C-start)]*100% - wherein:
- VT-end: the mean value of tumor volume of a treatment group at the end of the test;
- VT-start: the mean value of tumor volume of a treatment group at the beginning of the test;
- VC-end: the mean value of tumor volume of a vehicle group at the end of the test;
- and
- VC-start: the mean value of tumor volume of a vehicle group at the beginning of the test.
- 5.2 Body Weight: The Body Weight of an Animal was Measured Twice a Week.
- 6. Test Results
- 6.1 the Effects on Gastric Cancer Cell NCI-N87
- 6.1.1 Tumor Regression
- Compared with the vehicle control group and the positive control (gemcitabine injection) group, in the groups treated with C8 samples, the tumor growth was significantly inhibited, and various routes of administration of C8 were shown to be safe and well tolerated.
- The results of TGI and tumor regression of each group are shown in Table 2.
- The results indicated that in the groups treated with C8, complete tumor regression occurred in all the animals, while in the group treated with a gemcitabine injection, complete tumor regression occurred in 2 animals, and partial tumor regression occurred in 6 animals.
-
TABLE 2 the results of TGI and tumor regression in a model of gastric cancer cell NCI-N87. Adminis- Dosage tration TGI Tumor Group Compound (μmol/kg) route (%) regression 1 Vehicle control — i.v. / 0 2 Gemcitabine 190 i.v. 107 2/8 CR, 6/8 PR 4 Compound C8 190 i.v. 109 8/8 CR 5 Compound C8 190 p.o. 110 8/8 CR Note: CR represents complete tumor regression; PR represents partial tumor regression, i.e., the tumor volume is smaller than that at the beginning of the administration; i.v. represents intravenous administration; and p.o. represents oral administration. - 6.1.2 Body Weight Change and Mortality of the Animals
- At the end of the observation (which was continued for 14 days after the last administration), the body weight of the animals increased in all the groups compared with the weight at the beginning of the administration, and no animal deaths occurred in each group. The results are shown in Table 3.
-
TABLE 3 body weight change and mortality of the animals in each group Adminis- Dosage tration Body weight Group Compound (μmol/kg) route change 1 Vehicle control — i.v. +11.9% 2 Gemcitabine injection 190 i.v. +4.8% 4 Compound C8 190 i.v. +8.1% 5 Compound C8 190 p.o. +8.1% - On the one hand, in the test on mice bearing a tumor of gastric cancer cell line NCI-N87, compared with the vehicle control group, in the group treated with a gemcitabine injection, complete tumor regression occurred in 2 animals, and partial tumor regression occurred in 6 animals; while complete tumor regression occurred in all the animals from the groups treated with intravenous administration and oral administration of C8, indicating that the tumor growth in animals from groups treated with C8 (i.v. and p.o.) was significantly inhibited.
- On the other hand, no animal death occurred in any of the treatment groups. The body weight of the animals increased to different degrees in all the groups, compared with the weight at the beginning of the administration. It was surprisingly found that the percentage body weight increase in the groups treated with compound C8 were twice as much as that in the group treated with a gemcitabine injection. It is shown that the test compound of the present application has significant pharmacological efficacy, as well as better safety and tolerability profiles, and an organism treated with it would recover more easily.
- 6.2 Colorectal Cancer Cell HCT-116
- 6.2.1 Tumor Regression
- Compared with the vehicle control group and the positive control (gemcitabine injection) group, in the groups treated with compound C8, the tumor growth was significantly inhibited, and compound C8 was shown to have excellent safety and tolerability profiles.
- The results of TGI and tumor regression of each group are shown in Table 4.
- The results (obtained from observation at 14 days after the last administration) indicated that in the groups treated with compound C8 (i.v. and p.o.), complete tumor regression occurred in 1 animal, and partial tumor regression occurred in 7 animals; while no tumor regression occurred in the group treated with a gemcitabine injection.
-
TABLE 4 the results of TGI and tumor regression in a model of colorectal cancer cell HCT-116. Adminis- Dosage tration TGI Tumor Group Compound (μmol/kg) route (%) regression 1 Vehicle control — i.v. / 0 2 Gemcitabine 190 i.v. 92 0 4 Compound C8 190 i.v. 111 1/8 CR, 7/8 PR 5 Compound C8 190 p.o. 113 1/8 CR, 7/8 PR - 6.2.2 Body Weight Change and Mortality of the Animals
- At the end of the observation (which was continued for 14 days after the last administration), the body weight of the animals decreased (by 2.4%) in the group treated with a gemcitabine injection, while the body weight of the animals increased in all the remaining groups, compared with the weight at the beginning of the administration. No animal deaths occurred in any of the groups. The detailed results are shown in Table 5.
-
TABLE 5 body weight change and mortality of the animals in each group Adminis- Body Dosage tration weight Group Compound (μmol/kg) route change Mortality 1 Vehicle control — i.v. +8.6% 0 2 Gemcitabine 190 i.v. −2.4% 0 4 Compound C8 190 i.v. +7.4% 0 5 Compound C8 190 p.o. +8.9% 0 - In the test on mice bearing a tumor of colorectal cancer cell line HCT-116, compared with the vehicle control group, no tumor regression occurred in the group treated with a gemcitabine injection; while in the groups treated with compound C8 (including intravenous administration and oral administration), complete tumor regression occurred in 1 animal, and partial tumor regression occurred in 7 animals. It was thus demonstrated that compound C8 had an excellent anti-tumor effect in vivo. Meanwhile, compound C8 has good polarity and lipid solubility, as well as improved metabolic properties and bioavailability.
- 1. Cell Lines for the Test, Tumor Cell Inoculation, and Grouping of Animals
- According to methods similar to those in sections 1 to 2 in Experimental example 2, pancreatic cancer cell BxPC-3 was cultured as a monolayer in vitro, and inoculated, and the animals were randomized into groups.
- 2. Sample Preparation
- Sulfobutyl ether-β-cyclodextrin (SE-β-CD) was formulated with physiological saline to form a 10% solution, which was then filtered through a 0.22 μm sterile filter for later use. An appropriate amount of the test compound was weighted out, and added in DMSO. The 10% solution of SE-β-CD was then added according to the desired concentration, and the final concentration of DMSO was adjusted to 2.5%. A gemcitabine injection (a positive control) was diluted to the desired concentration with physiological saline. A 10% solution of SE-β-CD containing 2.5% DMSO was prepared as a vehicle control.
- 3. Test Method
- Mice bearing a tumor having a volume of 100-200 mm3 were selected, and randomized into 14 groups (7 mice per group). The dosing volume was 20 mL/kg, and the administration (intravenous administration (i.v.)) was performed once every 3 days, for 4 times in total. The tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- 4. Test Indexes
- For statistical calculations of the test indexes, please refer to Experimental example 2.
- 5. Test Results
-
TABLE 6 the efficacy on a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse Administration Compound Dosage (mmol/kg) route TGI (%) Vehicle control / i.v. — Gemcitabine injection 0.04 i.v. −2.2 Compound C8 0.04 i.v. 26.9 Gemcitabine injection 0.12 i.v. 28.9 Compound C8 0.12 i.v. 74.9 Gemcitabine injection 0.24 i.v. 45.5 Compound C8 0.24 i.v. 82.9 - As can be seen from the table above, compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection.
- 1. Cell Lines for the Test, Tumor Cell Inoculation, Grouping of Animals, and Sample Preparation
- According to methods similar to those in sections 1 to 3 in Experimental example 2, pancreatic cancer cell BxPC-3 was cultured as a monolayer in vitro, and inoculated; the animals were randomized into groups; and samples were prepared.
- 2. Test Method
- Mice bearing a tumor having a volume of 80-250 mm3 were selected, and randomized into 6 groups (8 mice per group). The dosing volume was 10 mL/kg. The tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- 3. Test Indexes
- For statistical calculations of the test indexes, please refer to Experimental example 2.
- 4. Test Results
- The test results obtained by administrating twice a week for 3 weeks in total are shown in table 7-1.
-
TABLE 7-1 the efficacy on a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse Administration Compound Dosage (mmol/kg) route TGI (%) Vehicle control / p.o. / Compound C8 0.06 p.o. 47.7 Gemcitabine injection 0.12 i.v. 23.6 Compound C8 0.12 p.o. 53.2 - The test results obtained by administrating (intravenous administration (i.v.) or oral administration (p.o.)) once a week for 3 weeks are shown in table 7-2.
-
TABLE 7-2 the efficacy on a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse Administration Compound Dosage (mmol/kg) route TGI (%) Gemcitabine injection 0.23 i.v. 23.6 Compound C8 0.23 p.o. 51.0 - In this test, compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell BxPC-3 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection. Moreover, compound C8 exhibits excellent oral bioavailability. As oral administration is an administration route more acceptable to a patient, compound C8 of the present invention has improved tolerability in a patient.
- 1. Cell Lines for the Test, Tumor Cell Inoculation, and Grouping of Animals
- According to methods similar to those in sections 1 to 2 in Experimental example 2, pancreatic cancer cell Capan-1 was cultured as a monolayer in vitro, and inoculated, and the animals were randomized into groups.
- 2. Sample Preparation
- Samples were prepared as described in Experimental example 2.
- 3. Test Method
- Mice bearing a tumor having a volume of 100-200 mm3 were selected, and randomized into 7 groups (7 mice per group). The dosing volume was 20 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed once every 3 days, for 6 times in total. The tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
- 4. Test Indexes
- For statistical calculations of the test indexes, please refer to Experimental example 2.
- 5. Test Results
-
TABLE 8 the efficacy on a subcutaneous xenograft of human pancreatic cancer cell Capan-1 in a nude mouse Administration Compound Dosage (mmol/kg) route TGI (%) Vehicle control — p.o. — Gemcitabine injection 0.02 i.v. 15.4 Gemcitabine injection 0.19 i.v. 78.9 Compound C8 0.02 p.o. 25.6 Compound C8 0.06 p.o. 79.1 Compound C8 0.19 p.o. 138.5 Compound C8 0.06 i.v. 81.8 - As can be seen from the table above, compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell Capan-1 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection. Moreover, the effects achieved by oral and intravenous administration of compound C8 were better than that achieved by gemcitabine administrated in a dose three times higher than that of C8.
- This test was performed according to experimental example 5.
- Mice bearing a tumor having a volume of 100-200 mm3 were selected, and randomized into 4 groups (6 mice per group). The dosing volume was 10 mL/kg, and the administration (intravenous administration (i.v.) or oral administration (p.o.)) was performed once every 3 days, for 6 times in total. The tumor volume and body weight were measured twice a week after the administration, and the mortality of animals was observed every day.
-
TABLE 9 the efficacy on a subcutaneous xenograft of human pancreatic cancer cell PANC-1 in a nude mouse Administration Compound Dosage (mmol/kg) route TGI (%) Vehicle control — p.o. — Gemcitabine injection 0.06 i.v. 64.4 Compound C8 0.06 p.o. 155 Compound C8 0.19 p.o. 195 - As can be seen from the table above, compound C8 of the present invention can effectively inhibit the growth of a subcutaneous xenograft of human pancreatic cancer cell Capan-1 in a nude mouse at various dosages, and the pharmacological effect of compound C8 is significantly better than that of the gemcitabine injection.
- This experimental example was use to demonstrate the significantly improved safety profile of the compound of present invention.
- 1. Oral Toxicity Test in Mice (Administration for 7 Days)
- Normal Male and female Kunming mice (SPF grade, obtained from Laboratory Animal Center in Sichuan Academy of Chinese Medicine Science) were randomized by weight into groups. The test compound and vehicle control were formulated according to Experimental example 2. The dosage volume was 10 mL/kg, and the administration was performed by oral gavage, once per day for 7 consecutive days.
- The mortality and clinical symptoms observed in this test are shown in table 10.
-
TABLE 10 the results of mortality and clinical symptoms observed in mice administered repeatedly for 7 days Dosage Dosage Results Group Sample (mg/kg) (μmol/kg) (3 Male + 3 Female) 1 Purified water 0 0 No abnormal symptoms 2 Vehicle control 0 0 No abnormal symptoms 3 Compound C8 ~6 ~12 No abnormal symptoms 4 Compound C8 ~20 ~38 No abnormal symptoms 5 Compound C8 ~41 ~77 One animal arched, and then recovered. 6 Compound A ~20 ~77 The animals all exhibited severe abnormal symptoms, and two of them died. - According to the table above, the toxic reactions resulted from about 77 μmol/kg compound A caused the death of some animals, while the death caused by a dosage of about 77 μmol/kg of compound A occurred only when compound C8 was administered at a very high dosage (˜115 μmol/kg). Moreover, the animals survived at a dosage of about 77 μmol/kg of compound C8, which indicated that the toxic effects caused by oral administration of this compound to mice were mild, the mice can recover, and the reduced toxicity caused by oral administration of compound C8 to mice was thus demonstrated.
- 2. Intravenous Toxicity Test in Mice (Administration for 7 Days)
- This test was used to investigate the toxic reactions after intravenous administration of compound C8 to normal KM mice for 7 consecutive days.
- Test Method
- KM mice passing the quarantine control were randomized into 4 groups (3 mice/gender/group). The test compound and vehicle control were formulated according to Experimental example 2. The dosage volume was 10 mL/kg, and the specific dosages were as shown in table 11. The mortality, appearance, behavior, mental status, secretion and excreta etc. of the animals were observed every day for 7 consecutive days after the administration, and the animals were anatomized on day 8.
-
TABLE 11 dosages Dosage Dosage Group Drug (mg/kg) (μmol/kg) Animal number 1 Physiological saline 0 0 3 male + 3 female 2 Vehicle control 0 0 3 male + 3 female 3 Compound C8 60.9 115.38 3 male + 3 female 4 Compound A 20 76.92 3 male + 3 female - Test Results
- There was no significant difference of the indexes between the physiological saline group and the vehicle group.
- The animals from the group treated with compound A exhibited symptoms such as a hunched stance and weight loss, etc. on day 8, while no relevant abnormalities were observed in group 3 (the group treated with compound C8). The body weight of the animals treated with compound A decreased gradually, and on day 8, the body weight of the female and male mice decreased by 20.2% and 18.1%, respectively; while the body weight of the animals from the group treated with compound C8 increased gradually, and on day 8, the body weight of the female and male mice increased by 13.1% and 26.7%, respectively. Upon anatomy on day 8, compared with the vehicle group, the leukocyte count in the female and male animals from the group treated with compound C8 decreased by 45% and 49%, respectively, and the platelet count decreased by 43% and 39%, respectively; while the leukocyte count in the female and male animals from the group treated with compound A decreased by 83% and 87%, respectively, and the platelet count decreased by 71% and 77%, respectively.
- All the compounds in the examples were tested according to the methods described above, and it was found that the compounds in the examples of the present invention have substantially better safety profiles than those of gemcitabine injection and compound A in the toxicology experiments.
- By testing the compounds in the examples as described above, it was found that the compounds prepared in the present invention, whether administered intravenously or orally, all achieved excellent anti-tumor effects, and tumors showed complete regression or partial regression. More surprisingly, the pharmacological effects achieved by administering the compounds of the present invention via two different routes were all better than that of the gemcitabine injection (tumors showed no or less regression in the group treated with the gemcitabine injection), and the defect of poor oral bioavailability of gemcitabine was completely overcome.
- Unexpectedly, the body weight of the animals in the group treated with the gemcitabine injection decreased during the experiment, indicating that the injection caused certain damages to the test animals; while the body weight of animals in the groups treated with the compounds in the examples of the present invention increased during the experiment, indicating the compounds of the present invention have better tolerability and safety profiles in the animals in different groups.
- In summary, the 4′-thio-2′-fluoronucleoside compounds of the present invention have excellent pharmacological effects. Compared with the parent compound (compound A), the compounds of the present invention have increased lipid solubility, improved bioavailability, reduced irritation, improved absorption, and no issues in metabolic rate. The most critical breakthroughs of the compounds of the compounds of the present invention are significantly reduced toxicity, improved safety profile, and efficacy achieved through various routes of administration (intravenous or oral administration).
- The present invention has been further described through the above specific embodiments. However, it should not be construed that the scope of the present invention is merely limited to the above examples, technical solutions achieved based on the contents of the present invention all fall within the scope of the present invention.
Claims (15)
1. A method for the prevention or treatment of an abnormal cell proliferative disease in a mammal, wherein the method comprises administering to the mammal an effective amount of a compound selected from the group consisting of:
2. The method according to claim 1 , wherein the abnormal cell proliferative disease is cancer and/or tumor and related disorders thereof.
3. The method according to claim 1 , wherein the effective amount of the compound is in a unit dose ranging from 0.1-1000 mg.
4. The method according to claim 3 , wherein the effective amount of the compound is in a unit dose ranging from 1-800 mg.
5. The method according to claim 4 , wherein the effective amount of the compound is in a unit dose ranging from 10-600 mg.
6. The method according to claim 5 , wherein the effective amount of the compound is in a unit dose ranging from 50-450 mg.
7. The method according to claim 6 , wherein the effective amount of the compound is in a unit dose ranging from 100-300 mg.
8. The method according to claim 1 , wherein an additional anti-tumour agent is administered.
9. The method according to claim 1 , wherein the effective amount is in a single dose unit or in multiple dose units.
10. The method according to claim 2 , wherein the cancer and/or tumor and related disorders thereof is selected from the group consisting of cancers in esophagus, stomach, intestine, rectum, mouth, pharynx, larynx, lung, colon, breast, uterus, endometrium, ovary, prostate, testis, bladder, kidney, liver, pancreas, bone, connective tissue, skin, eye, brain and central nervous system, as well as thyroid cancer, leukemia, Hodgkin disease, lymphoma and myeloma.
11. The method according to claim 1 , wherein the compound is administered at a dosage range of 0.1-1000 mg/kg body weight per day.
12. The method according to claim 11 , wherein the compound is administered at a dosage range of 1-800 mg/kg body weight per day.
13. The method according to claim 12 , wherein the compound is administered at a dosage range of 10-600 mg/kg body weight per day.
14. The method according to claim 13 , wherein the compound is administered at a dosage range of 100-400 mg/kg body weight per day.
15. The method according to claim 14 , wherein the compound is administered at a dosage range of 120-250 mg/kg body weight per day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/851,217 US20200262860A1 (en) | 2015-04-03 | 2020-04-17 | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510157772.0 | 2015-04-03 | ||
CN201510157772 | 2015-04-03 | ||
PCT/CN2016/077519 WO2016155593A1 (en) | 2015-04-03 | 2016-03-28 | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
US201715558620A | 2017-09-15 | 2017-09-15 | |
US16/851,217 US20200262860A1 (en) | 2015-04-03 | 2020-04-17 | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/077519 Continuation WO2016155593A1 (en) | 2015-04-03 | 2016-03-28 | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
US15/558,620 Continuation US10662214B2 (en) | 2015-04-03 | 2016-03-28 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200262860A1 true US20200262860A1 (en) | 2020-08-20 |
Family
ID=57004251
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/558,620 Active US10662214B2 (en) | 2015-04-03 | 2016-03-28 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
US16/851,217 Abandoned US20200262860A1 (en) | 2015-04-03 | 2020-04-17 | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/558,620 Active US10662214B2 (en) | 2015-04-03 | 2016-03-28 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof |
Country Status (9)
Country | Link |
---|---|
US (2) | US10662214B2 (en) |
EP (1) | EP3279207B1 (en) |
JP (1) | JP6769000B2 (en) |
CN (2) | CN109553651B (en) |
AU (1) | AU2016240117C1 (en) |
CA (1) | CA2975990A1 (en) |
EA (1) | EA034375B1 (en) |
HK (2) | HK1232229A1 (en) |
WO (1) | WO2016155593A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2832740T3 (en) | 2012-03-28 | 2019-09-30 | Fujifilm Corporation | SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-beta-D-ARABINOFURANOSYL)CYTOSINE |
KR102010804B1 (en) | 2012-08-13 | 2019-08-14 | 후지필름 가부시키가이샤 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THE SAME |
TWI678373B (en) | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | Thionucleoside derivative or its salt and pharmaceutical composition |
JP6769000B2 (en) * | 2015-04-03 | 2020-10-14 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | A novel compound of 4'-thionucleoside, its preparation method, its pharmaceutical composition and its use |
KR102198656B1 (en) | 2016-08-31 | 2021-01-05 | 후지필름 가부시키가이샤 | Anti-tumor agent, anti-tumor effect enhancer and anti-tumor kit |
WO2018113592A1 (en) * | 2016-12-22 | 2018-06-28 | 四川科伦博泰生物医药股份有限公司 | Solid form of 4'-thio-2'-fluoronucleoside phosphamide compound and preparation method therefor and use thereof |
CN110573521B (en) * | 2017-06-29 | 2023-04-21 | 四川科伦博泰生物医药股份有限公司 | Process for preparing 4' -thionucleosides and intermediates in the process |
CN110831604B (en) * | 2017-09-01 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | Pharmaceutical composition, method and use for tumor treatment or prevention |
WO2019146130A1 (en) * | 2018-01-29 | 2019-08-01 | 富士フイルム株式会社 | Antitumor agent for biliary cancer and treatment method of biliary cancer |
JP7419259B2 (en) * | 2018-04-19 | 2024-01-22 | サウザーン リサーチ インスチチュート | 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer |
CN112770731A (en) * | 2018-11-28 | 2021-05-07 | 四川科伦博泰生物医药股份有限公司 | Oral pharmaceutical composition with 4' -thionucleoside compound as active ingredient, preparation method and application thereof |
EP4004013A4 (en) * | 2019-07-30 | 2023-08-09 | Pinotbio, Inc. | Dinucleotide compounds for treating cancers and medical uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128458A (en) | 1990-04-20 | 1992-07-07 | Southern Research Institute | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents |
WO1997038001A1 (en) * | 1996-04-09 | 1997-10-16 | Yamasa Corporation | 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES |
JPH1087687A (en) | 1996-04-09 | 1998-04-07 | Yamasa Shoyu Co Ltd | 5-substituted-1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)uracil |
GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
JP5379347B2 (en) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ, インコーポレーテッド | 4'-thionucleosides and oligomeric compounds |
US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
CN103987712B (en) * | 2011-07-19 | 2016-05-04 | 河南美泰宝生物制药有限公司 | 2 ', 3 '-dideoxy-2 '-α-fluoro-2 '-β-C-methyl nucleoside and its prodrug |
WO2014124430A1 (en) * | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
EP3004130B1 (en) * | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
TWI678373B (en) * | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | Thionucleoside derivative or its salt and pharmaceutical composition |
JP6769000B2 (en) * | 2015-04-03 | 2020-10-14 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | A novel compound of 4'-thionucleoside, its preparation method, its pharmaceutical composition and its use |
-
2016
- 2016-03-28 JP JP2017541855A patent/JP6769000B2/en active Active
- 2016-03-28 CN CN201811577363.6A patent/CN109553651B/en active Active
- 2016-03-28 WO PCT/CN2016/077519 patent/WO2016155593A1/en active Application Filing
- 2016-03-28 CA CA2975990A patent/CA2975990A1/en not_active Abandoned
- 2016-03-28 EA EA201791535A patent/EA034375B1/en unknown
- 2016-03-28 US US15/558,620 patent/US10662214B2/en active Active
- 2016-03-28 EP EP16771348.6A patent/EP3279207B1/en active Active
- 2016-03-28 AU AU2016240117A patent/AU2016240117C1/en active Active
- 2016-03-28 CN CN201680001812.5A patent/CN106661077B/en active Active
-
2017
- 2017-06-12 HK HK17105803.7A patent/HK1232229A1/en unknown
-
2018
- 2018-03-02 HK HK18103052.9A patent/HK1243424A1/en unknown
-
2020
- 2020-04-17 US US16/851,217 patent/US20200262860A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3279207A1 (en) | 2018-02-07 |
JP6769000B2 (en) | 2020-10-14 |
JP2018513832A (en) | 2018-05-31 |
EP3279207B1 (en) | 2024-01-24 |
AU2016240117A1 (en) | 2017-08-24 |
CN109553651A (en) | 2019-04-02 |
CA2975990A1 (en) | 2016-10-06 |
EA201791535A1 (en) | 2018-01-31 |
HK1243424A1 (en) | 2018-07-13 |
US20180079770A1 (en) | 2018-03-22 |
CN106661077B (en) | 2019-02-12 |
EA034375B1 (en) | 2020-01-31 |
CN109553651B (en) | 2021-08-06 |
WO2016155593A1 (en) | 2016-10-06 |
AU2016240117C1 (en) | 2020-11-26 |
EP3279207A4 (en) | 2018-11-14 |
AU2016240117B2 (en) | 2020-08-06 |
HK1232229A1 (en) | 2018-01-05 |
US10662214B2 (en) | 2020-05-26 |
CN106661077A (en) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200262860A1 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
US10174067B2 (en) | Type of cytidine derivative and application thereof | |
JPS63239294A (en) | Novel adenosine derivative and medicinal composition containing said compound as active ingredient | |
WO2010036213A1 (en) | 3-deazaneplanocin derivatives | |
US10500224B2 (en) | Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment | |
KR20060127906A (en) | 4'-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity | |
CN111918870B (en) | Deuterated oligonucleotides and prodrugs | |
US10751358B2 (en) | Multitargeted nucleoside derivatives | |
CN111655710B (en) | Gemcitabine phosphorus-containing prodrugs | |
CN104072558B (en) | 5-substituted pyrimidines nucleoside-tetrahydro-thiazoles hybrid with HIV (human immunodeficiency virus)-resistant activity and preparation method thereof | |
US20230416294A1 (en) | Decitabine analogs for immunological and oncological therapy | |
US20240024347A1 (en) | Prodrugs of 6-mercaptopurine | |
US20220281904A1 (en) | A prodrug platform useful to deliver amines, amides and phenols | |
AU2022339679A1 (en) | 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment | |
WO2023034617A1 (en) | 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |